

Mechanism of replication fork reversal and protection by human RAD51 and RAD51 paralogs

Petr Cejka (✉ petr.cejka@irb.usi.ch)

Institute for Research in Biomedicine

Swagata Halder

University of Oxford

Aurore Sanchez

Institut Curie

Lepakshi Ranjha

Institute for Research in Biomedicine

Angelo Tagliatela

Columbia University Medical Center

Giordano Reginato

Institute for Research in Biomedicine Bellinzona

Ilaria Ceppi

Universita della Svizzera Italiana

Ananya Acharya

Universita della Svizzera Italiana

Roopesh Anand

Universita della Svizzera Italiana

Alberto Ciccia

Columbia University Medical Center <https://orcid.org/0000-0003-4789-6564>

Article

Keywords:

Posted Date: December 2nd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1096289/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Mechanism of replication fork reversal and protection by human RAD51 and RAD51 paralogs**

2

3 Swagata Halder¹, Aurore Sanchez¹, Lepakshi Ranjha¹, Angelo Taglialatela², Giordano Reginato^{1,3},
4 Ilaria Ceppi^{1,3}, Ananya Acharya^{1,3}, Roopesh Anand¹, Alberto Ciccia² and Petr Cejka^{1,3*}

5

6

7 ¹Institute for Research in Biomedicine, Università della Svizzera italiana (USI), Faculty of Biomedical
8 Sciences, Bellinzona, Switzerland

9 ²Department of Genetics and Development, Herbert Irving Comprehensive Cancer Center, Columbia
10 University Irving Medical Center, New York, NY, USA.

11 ³Department of Biology, Institute of Biochemistry, Eidgenössische Technische Hochschule (ETH), Zü-
12 rich, Switzerland

13

14

15 * To whom correspondence should be addressed. Tel: +41 91 820 03 61; Fax: +41 91 820 03 05; Email:
16 petr.cejka@irb.usi.ch

17

18

19

20 **ABSTRACT**

21

22 **SMARCAL1, ZRANB3 and HLTF are all required for the remodeling of replication forks upon**
23 **stress. Using reconstituted reactions, we show that the motor proteins have unequal biochemical**
24 **capacities, explaining why they have non-redundant functions. Whereas SMARCAL1 uniquely**
25 **anneals RPA-coated ssDNA, suggesting an initial function in fork reversal, it becomes compara-**
26 **tively inefficient in subsequent branch migration. We also show that low concentrations of RAD51**
27 **and the RAD51 paralog complex, RAD51B-RAD51C-RAD51D-XRCC2 (BCDX2), directly stim-**
28 **ulate SMARCAL1 and ZRANB3 but not HLTF, providing a mechanism underlying previous**
29 **cellular data implicating these factors in fork reversal. Upon reversal, RAD51 protects replication**
30 **forks from degradation by MRE11, DNA2 and EXO1 nucleases. We show that the protective**
31 **function of RAD51 unexpectedly depends on its binding to double-stranded DNA, and higher**
32 **RAD51 concentrations are required for DNA protection compared to reversal. Together, we de-**
33 **fine the non-canonical functions of RAD51 and its paralogs in replication fork reversal and pro-**
34 **tection.**

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50 INTRODUCTION

51 Homologous recombination (HR) is one of the key cellular pathways required for the maintenance of
52 genome stability. Historically, recombination proteins have been mostly studied in the context of DNA
53 double-strand break (DSB) repair^{1,2}. The first step in recombinational repair of broken DNA is DNA
54 end resection, where specialized nucleases degrade 5'-terminated DNA strands at the DSB sites, leading
55 to 3' overhangs. Resection is typically initiated by the MRE11 nuclease acting within the MRE11-
56 RAD50-NBS1 (MRN) complex in conjunction with CtIP. The ensemble first nicks 5'-terminated DNA
57 strand near the break end³. It has the unique capacity to nick past protein blocks, such as stalled topoi-
58 somerases or the Ku heterodimer, or past secondary DNA structures, which initiates processing of DNA
59 breaks. The 3'-5' exonuclease of MRN is subsequently believed to degrade DNA between the nick sites
60 and back towards the broken end, resulting in 3' overhangs of limited length⁴. The initial short-range
61 resection by MRN-CtIP is in most cases extended by either of two long-range nucleases, EXO1 or
62 DNA2, which functions together with the Bloom (BLM) or Werner (WRN) helicase⁵.

63 Downstream of resection in DSB repair, the ssDNA overhang is first coated by the single-strand DNA
64 (ssDNA) binding protein Replication Protein A (RPA). In the next step, RPA is replaced by RAD51, a
65 key recombinase in eukaryotic cells. The replacement of RPA and loading of RAD51 on the ssDNA
66 overhang is facilitated by a group of proteins termed as recombination mediators, which include the
67 BRCA2 protein, and the RAD51 paralog complexes, either RAD51B-RAD51C-RAD51D-XRCC2
68 (BCDX2), or RAD51C-XRCC3 (CX3)^{1,2,6,7,8}. These proteins catalyze the formation of the RAD51
69 nucleoprotein filament, which has the capacity to identify, pair, and invade homologous double-
70 stranded DNA (dsDNA). In vegetative cells, the homologous DNA is typically the sister chromatid that
71 carries the identical genetic sequence. Once the RAD51 nucleoprotein filament invades homologous
72 DNA, the 3'-terminated end serves as a primer for DNA synthesis that recovers any missing genetic
73 information near the break site. The joint molecule intermediates are subsequently matured and pro-
74 cessed to yield two recombined molecules, thus restoring genome integrity in a largely error-free man-
75 ner. The function of recombination factors in the context of DSB repair is now relatively well under-
76 stood^{1,2}.

77 More recently, it has been discovered that several recombination proteins have separate DSB repair-
78 independent functions in the response to replication stress^{9,10}. When replicating damaged templates,
79 repetitive DNA sequences or DNA at telomeres, during replication-transcription conflicts or upon the
80 overexpression of oncogenes, the forks can uncouple and the leading strand polymerase may transiently
81 stall¹¹. Upon prolonged stalling, depending on the cellular context, replication can restart by PRIMPOL-
82 mediated repriming, or the forks can undergo reversal^{12,13,14}. Fork reversal involves annealing of the
83 two nascent DNA stands yielding a 4-way junction, followed by branch migration^{15,16,17}. In contrast to
84 DSB repair, the functions of recombination proteins under replication stress remain mostly undefined.

85 For a long time, fork reversal was thought to be only a pathological process¹⁸. More recent data however
86 uncovered that depending on the context and cellular genetic background, fork reversal may be benefi-
87 cial^{15, 16, 19}. Fork reversal may in fact limit the extent of ssDNA at stalled forks, provide cells time to
88 deal with the respective challenge, and in this way prevent DNA breakage or even enables specific
89 DNA repair. Indeed, several motor proteins with unique capacities to reverse replication forks have
90 been identified, including but not limited to SMARCAL1, ZRANB3 and HLTF^{16, 20}. Depletion of
91 SMARCAL1 and ZRANB3 results in sensitivity to conditions inducing replication stress and enhancing
92 genome instability, indicating that fork reversal catalyzed by these enzymes in wild type cells can be a
93 protective process^{21, 22, 23, 24, 25, 26}.

94 In certain conditions, uncoupling of leading and lagging strand DNA synthesis may result in the for-
95 mation of ssDNA gaps, which together with aberrant fork reversal can lead to DNA degradation and
96 genome instability. Gaps of ssDNA on newly synthesized daughter strand or on the apex of the reversed
97 replication fork represent entry points for pathological nucleolytic degradation, unless stabilized by
98 RAD51^{10, 16, 27}. The degradation of nascent DNA can be particularly observed in cells with impaired
99 functions of BRCA1, BRCA2 and a growing number of additional factors, which are believed to recruit
100 and stabilize RAD51 on DNA, or otherwise directly or indirectly inhibit the respective nucleases^{9, 17, 19,}
101 ^{28, 29}. Remarkably, the same pro-DNA end resection nucleases that promote DSB repair, including
102 MRE11 (presumably within the MRN complex), EXO1 and DNA2 were shown to contribute to the
103 pathological nascent DNA degradation in various genetic backgrounds^{28, 30, 31, 32, 33, 34}. Notably, degra-
104 dation of reversed forks by DNA2 in wild type cells may mediate fork restart³⁵. The function of BRCA2
105 in fork protection is genetically separable from its function in DSB repair, showing that there are distinct
106 mechanisms at play⁹. How RAD51 protects nascent DNA remains uncharacterized, but it has been as-
107 sumed that RAD51 binding to ssDNA on the regressed arm of the reversed forks serves as a barrier
108 against the entry of the resection nucleases^{16, 27}.

109 Cellular data suggest that the impaired RAD51 function to protect stalled forks in BRCA-deficient cells
110 results in extended degradation of nascent DNA of multiple kilobases in length⁹. Such DNA degradation
111 is dependent on the proteins implicated in fork reversal, including SMARCAL1, ZRANB3 and HLTF,
112 which suggested that reversed, but not stalled replication forks are primarily subjected to degradation^{9,}
113 ^{27, 30, 31, 36}. However, nascent DNA degradation is not observed upon depletion of RAD51 itself^{17, 31}. This
114 apparently paradoxical observation was explained by a model where RAD51 also promotes fork rever-
115 sal. Accordingly, in the absence of RAD51, the substrates for DNA degradation, i.e. reversed forks, are
116 not formed. In the absence of the relevant substrate, the function of RAD51 in fork protection becomes
117 irrelevant, explaining why nascent DNA is stable upon depletion of RAD51^{17, 37}. The function of
118 RAD51 in fork reversal, in contrast to DNA protection, is independent of BRCA2^{9, 31}. How mechanis-
119 tically RAD51 promotes replication fork reversal remains undefined, but it appears to be distinct from
120 its function in canonical recombination³⁸. Similarly as with BRCA2, the function of RAD51 in DSB

121 repair and fork metabolism/modulation is genetically separable³⁸. Recently, the BCDX2 RAD51 pa-
122 ralog complex was found to promote fork reversal alongside RAD51 in cellular assays³⁹.

123 The seemingly paradoxical situation where RAD51 may both promote and prevent DNA degradation
124 highlights the difficulties explaining cellular phenotypes and thus warrants the need for a more direct
125 understanding of the underlying mechanisms³⁷. Here we use reconstitution biochemistry, which allows
126 us to study elements of the reactions governing the metabolism of challenged replication forks in isola-
127 tion. We show that the fork remodelers SMARCAL1, ZRANB3 and HLTf have different substrate
128 preferences, suggesting that they may catalyze different reactions and thus act at distinct steps during
129 fork remodeling, explaining cellular data why these factors have non-redundant functions. We show
130 that RAD51 and the BCDX2 RAD51 paralog complex directly promote the motor-driven strand an-
131 nealing activity of SMARCAL1 and ZRANB3, which identifies the mechanism by which RAD51 and
132 BCDX2 may facilitate fork reversal. We show that compared to fork reversal, higher RAD51 concen-
133 trations are required for DNA protection against MRE11-RAD50 exonuclease, MRN endonuclease,
134 and EXO1 and DNA2 nucleases. In contrast to the current models, we demonstrate that the protective
135 function of RAD51 also involves its capacity to bind dsDNA. Together, our data provide comprehen-
136 sive insights into the mechanisms underlying the function of RAD51 and RAD51 paralogs in the me-
137 tabolism of challenged replication forks.

138

139

140

141 RESULTS

142

143 SMARCAL1, ZRANB3 and HLTF have unequal biochemical activities

144 SMARCAL1, ZRANB3 and HLTF have all been implicated in replication fork reversal *in vitro* and *in vivo*^{22, 40, 41}. The loss of either of these enzymes was shown to abolish nascent DNA degradation in
145 BRCA1/2-deficient cells, suggesting that these factors may act in a non-redundant manner to promote
146 fork reversal¹⁹. To better understand the function of these fork remodelers, we expressed and purified
147 SMARCAL1, ZRANB3 and HLTF from insect *Sf9* cells (Fig. 1a). All three translocases hydrolyzed
148 ATP, as expected, with SMARCAL1 showing the highest specific activity, followed by HLTF and
149 ZRANB3 (Supplementary Fig. 1a). We next set out to compare the relative activities of these motor
150 proteins in biochemical assays mimicking elements of fork reversal. We first used oligonucleotide-
151 based DNA substrates resembling stalled replication forks with ssDNA gaps either in the leading or the
152 lagging DNA strand (Fig. 1b). We observed, as reported previously, that SMARCAL1 in the presence
153 of the ssDNA binding protein RPA was more efficient on forks with leading strand gaps, as opposed to
154 ZRANB3, which prefers RPA on lagging strand gaps⁴² (Fig. 1c). Using the leading strand gap substrate,
155 SMARCAL1 was also more efficient than HLTF (Fig. 1c), while the three translocases exhibited similar
156 specific activities on the lagging strand gap substrate (Fig. 1c). In contrast to the activities of
157 SMARCAL1 and ZRANB3 that are regulated by RPA⁴², the function of HLTF was not RPA sensitive
158 (Fig. 1d). During fork reversal, the initial annealing of the nascent DNA strands leads to the formation
159 of a 4-way junction (Holliday junction, HJ), which is further branch migrated by the motor proteins,
160 leading to reversed forks of up to several kilobases in length¹⁶. Using a mobile HJ substrate to assay for
161 branch migration, we observed that SMARCAL1 was in contrast the least efficient enzyme, essentially
162 incapable of branch migration at physiological (150 mM) salt concentrations. However, under less re-
163 strictive conditions in lower salt, the branch migration activity of SMARCAL1 was readily detected
164 (Fig. 1f, right panel). Instead, both ZRANB3 and HLTF were highly and comparably efficient in branch
165 migration at 150 mM salt (Fig. 1e, f).

167 The activity of the SMARCAL1 and ZRANB3 enzymes was first analyzed by a topoisomerase-coupled
168 assay that monitors the annealing of RPA-coated ssDNA bubbles in plasmid DNA, which can be ob-
169 served as changes in DNA topology^{25, 43, 44}. Such activity is thought to mimic the initial stages of fork
170 remodeling. Both SMARCAL1 and ZRANB3 were shown to anneal the RPA-coated DNA bubbles as
171 a result of their motor functions, as ATP hydrolysis is required for this reaction. However, the specific
172 activities of SMARCAL1 and ZRANB3 have not been compared. We observed that SMARCAL1 was
173 comparably efficient to ZRANB3, while HLTF showed much smaller capacity to anneal DNA in this
174 assay (Fig. 1g, h).

175 Taken together, our data indicate that SMARCAL1, ZRANB3 and HLTF possess quite different bio-
176 chemical activities and substrate preferences. Our results support a model positing that fork reversal is
177 not catalyzed by a single enzyme in a processive manner, but that it is rather a dynamic process that
178 involves the sequential engagement of several factors.

179

180 **SMARCAL1 specifically anneals RPA-coated ssDNA**

181 Several helicases, such as members of the RecQ family, were reported to anneal two ssDNA molecules,
182 but the reactions were inhibited by RPA^{45, 46}. Considering that cellular RPA concentration is thought to
183 be sufficient to coat all ssDNA in most cases, the physiological relevance of these observations remains
184 unclear. In this regard, the reported activities of the RecQ family members differ from the canonical
185 RecO/RAD52 family annealing proteins, which anneal RPA-coated ssDNA to promote homologous
186 recombination^{47, 48}. The observation that SMARCAL1 and ZRANB3 are efficient in annealing bubbled
187 DNA coated with RPA prompted us to investigate whether the enzymes can anneal two ssDNA mole-
188 cules similarly as RAD52. The annealing of the bubbled DNA in the topoisomerase-coupled assays
189 could result from an annealing activity *per se*, or can be a consequence of the dsDNA translocase ac-
190 tivity re-zipping the bubble from the side. To distinguish between these two possibilities, we set to define
191 the function of the fork remodelers in complementary ssDNA annealing. We observed that
192 SMARCAL1, ZRANB3 and HLTF were all able to anneal free ssDNA, which can be explained by
193 multiple ssDNA binding sites on a single enzyme or by enzyme oligomerization, which can bring mul-
194 tiple ssDNA molecules to close proximity, stimulating their annealing. However, in the presence of
195 RPA, the ssDNA annealing by ZRANB3 and HLTF was strongly reduced, similarly as observed with
196 the RecQ family helicases⁴⁵. In contrast, ssDNA annealing by SMARCAL1 remained highly proficient
197 in the presence of RPA (Fig. 2a, b, c). Unlike RPA, the ssDNA annealing capacity of SMARCAL1 was
198 abrogated when the ssDNA was pre-coated with mitochondrial SSB, showing that the annealing of
199 ssDNA by SMARCAL1 is allowed in the presence of RPA in a specific manner (Fig. 2d). The annealing
200 activity of SMARCAL1 was also observed in the absence of ATP, or when using the motor-dead
201 SMARCAL1 (D549A, E550A, SMARCAL1-HD) variant showing that this particular activity is not
202 ATPase dependent (Supplementary Fig. 2a), as is the case of RAD52⁴⁸. Therefore, the annealing of two
203 ssDNA molecules by SMARCAL1 mechanistically differs from the annealing of bubbled DNA in the
204 topoisomerase coupled assays, which largely require ATP hydrolysis^{25, 43, 44}.

205 The N-terminal region of SMARCAL1 contains a previously defined RPA-binding site, the integrity of
206 which is required for the recruitment of SMARCAL1 to DNA damage sites, and to direct SMARCAL1
207 to substrates with RPA-coated ssDNA gaps²¹ (Fig. 2e). To test for the requirement for direct interaction
208 between SMARCAL1 and RPA in ssDNA annealing, we expressed and purified SMARCAL1 (Δ N),
209 lacking the RPA interaction domain (Fig. 2f). The truncated SMARCAL1 was fully proficient in DNA

210 branch migration in the absence of RPA and identical to wild type SMARCAL1 as an ATPase (Sup-
211 plementary Fig. 2b, c). However, the mutant was inefficient in ssDNA annealing in the presence of
212 RPA, showing that the direct interaction of SMARCAL1 with RPA is essential for this activity (Fig.
213 2g). Our results reveal that SMARCAL1 possesses a strand annealing activity similar to that of the
214 RAD52 protein family, which also rely on specific interaction with RPA⁴⁸. We suggest that such activity
215 may be employed during the very initial steps of fork reversal, when the daughter ssDNA molecules
216 are separated from the parental strands and anneal with each other. These results further underline the
217 mechanistic differences between the fork remodeling enzymes SMARCAL1, ZRANB3 and HLTF.

218

219 **RAD51 and BCDX2 paralogs promote motor-driven strand annealing activity of SMARCAL1** 220 **and ZRANB3 but not HLTF**

221 Challenged DNA replication forks may undergo reversal, and reversed replication forks must be sub-
222 sequently protected by RAD51 to prevent pathological nascent DNA degradation^{9, 10, 15, 16, 49}. However,
223 RAD51, along with the RAD51 paralog BCDX2 complex, were also paradoxically implicated in pro-
224 moting fork reversal, through a yet unknown mechanism^{17, 39}. To elucidate whether the function of
225 RAD51 and the RAD51 paralogs in fork remodeling may be direct, we next expressed and purified
226 RAD51 and the BCDX2 complex (Fig. 3a). The BCDX2 complex was obtained upon co-expression of
227 all subunits, as the preparation of the individual proteins resulted in poor yields and solubility. The
228 BCDX2 complex did not aggregate, bound ssDNA and very weakly hydrolyzed ATP, as observed pre-
229 viously (Supplementary Fig. 3a-d)⁵⁰.

230 We next set out to test whether RAD51 and BCDX2 complex affect the strand annealing and motor
231 activities of SMARCAL1. To this point, we used the established topoisomerase-coupled assay^{25, 43, 44}.
232 Strikingly, we observed that low concentrations of RAD51 and the BCDX2 complex promoted bubbled
233 DNA annealing by SMARCAL1, while none of these co-factors had a notable capacity to mediate DNA
234 annealing *per se* without SMARCAL1, even at much higher concentrations (Fig. 3b, Supplementary
235 Fig. 3e, f). Additionally, controls where no ATP was used or helicase-dead SMARCAL1 variant re-
236 placed the wild type protein largely abolished DNA annealing, indicating that a large proportion of the
237 relaxed DNA signal in the assay can be linked to the ATP hydrolysis-driven translocation activity of
238 SMARCAL1 (Fig. 3b, Supplementary Fig. 3g). Similarly to SMARCAL1, we observed that RAD51
239 and the BCDX2 paralogs promoted the annealing capacity of ZRANB3. As above with SMARCAL1,
240 we observed that RAD51 and BCDX2 could both promote ZRANB3 independently of each other (Fig.
241 3c). Only limited changes in DNA topology were observed when using helicase-dead ZRANB3 and all
242 co-factors, demonstrating that the majority of the signal in the assay can be linked to the motor activity
243 of ZRANB3 leading to DNA annealing (Supplementary Fig. 3h).

244 Differently from SMARCAL1 and ZRANB3, HLTf was not stimulated by either RAD51 or BCDX2
245 (Fig. 3d). The RAD51C-XRCC3 (CX3) complex could also promote DNA annealing with both
246 SMARCAL1 and ZRANB3 (Supplementary Fig. 3i, j, k), despite it has not been found to promote fork
247 reversal *in vivo*^{39,51}. While the CX3 complex may not be efficiently recruited to physiological substrates
248 in cells, the experiments were informative as they revealed that the critical component of the paralogs
249 may be RAD51C, which is present in both BCDX2 and CX3 complexes. Together, we show that
250 RAD51 and BCDX2 promote the translocation-driven annealing of RPA-coated bubbled DNA by
251 SMARCAL1 and ZRANB3, suggesting that the co-factors may have a direct role in fork reversal to
252 stimulate the DNA translocases.

253

254 **SMARCAL1 and ZRANB3 physically interact with RAD51 and BCDX2**

255 To test whether the functional interplay between SMARCAL1 and ZRANB3 with RAD51 and BCDX2
256 may involve direct physical interactions, we immobilized RAD51 and performed pulldown experiments
257 with the co-factors. We observed that BCDX2 interacted with RAD51 (the RAD51B component was
258 detected), as described previously⁵². Importantly, we found that both SMARCAL1 and ZRANB3 also
259 interacted with RAD51 (Fig. 4a). We next immobilized the BCDX2 complex, and observed a direct
260 interaction with SMARCAL1 and ZRANB3, as detected by Western blotting and silver staining (Fig.
261 4b, c). These results collectively suggest that the interplay of SMARCAL1 and ZRANB3 with RAD51
262 and BCDX2 likely involves direct physical interactions.

263

264 **Point mutation in SMARCAL1 disrupts physical and functional interactions with RAD51**

265 We next set out to define motifs in SMARCAL1 and ZRANB3 that mediate the interactions with
266 RAD51 and BCDX2. We failed to identify an interaction motif with BCDX2, but we found regions in
267 SMARCAL1 mediating the binding to RAD51. Physical and functional interactions between RAD51
268 and many of its co-factors, such as BRCA2, BARD1, MMS22L, RECQL5, SWSAP1 and FINGL1 are
269 mediated by the FXXA motif^{53, 54, 55, 56, 57, 58}. We identified such a motif in SMARCAL1, which is
270 conserved in evolution (Fig. 4d, Supplementary Fig. 4a). The FXXA motif is positioned ahead of the
271 conserved α I SNF2 family ATPase domain (Supplementary Fig. 4b). The mutation of phenylalanine
272 446 into alanine (F446A) in SMARCAL1 disrupted the physical interaction with RAD51 (Fig. 4e, f).
273 In contrast, disruption of F439, which is part of a less conserved FXXA sequence in human
274 SMARCAL1 upstream of F446, did not impair the interaction (Fig. 4f, Supplementary Fig. 4a). We
275 note that SMARCAL1 F446A variant *per se* was very similar to wild type SMARCAL1 in its fork
276 reversal and ATPase capacities *in vitro* and retained its physical interaction with the BCDX2 complex
277 (Supplementary Fig. 4c, d and Fig. 4g). ZRANB3 contains a phenylalanine at the analogous position to

278 SMARCAL1 ahead of the ATPase domain. The phenylalanine however does not conform to the FXXA
279 motif, and the F47A substitution mutant retained its capacity to interact with RAD51 and was impaired
280 in its ATPase activities (Supplementary Fig. 4e-h). We next found that mutation F736A in ZRANB3
281 disrupted interaction with RAD51, however it is likely that the mutation affected the fold of the sub-
282 strate recognition domain, as it likewise abolished the biochemical activities of ZRANB3 and may thus
283 not represent a direct interaction motif (Supplementary Fig. 4i-k)⁵⁹. Due to the impact of this mutation
284 on the activities of ZRANB3 *per se*, we could not test for the physiological relevance of the interaction
285 with RAD51.

286 To investigate the physiological relevance of the disrupted physical interaction between SMARCAL1
287 and RAD51, we used MCF10A SMARCAL1-KO cells³⁶, which were complemented with either wild
288 type SMARCAL1 or the F446A variant (Fig. 4h). Following replication stress induced by hydroxyurea,
289 it was previously demonstrated that SMARCAL1-mediated fork reversal can lead to nascent DNA deg-
290 radation, as long as the nascent DNA is not protected by RAD51³⁶. The nascent DNA degradation is
291 evident in cells lacking BRCA1 or BRCA2, which may be required to recruit, load or stabilize RAD51.
292 In agreement with previous data³⁶, we observed extensive nascent DNA degradation in BRCA1-
293 depleted SMARCAL1 KO cells reconstituted with wild type SMARCAL1 (Fig. 4h). In contrast, such
294 extensive DNA degradation was not observed in BRCA1-depleted SMARCAL1 KO cells reconstituted
295 with empty vector (no SMARCAL1), and it was partially attenuated in cells with SMARCAL1 F446A,
296 which was expressed at levels comparable to wild type (Supplementary Fig 4i). Taking into considera-
297 tion that nascent DNA degradation in BRCA-deficient cells requires the fork reversal activity of
298 SMARCAL1³⁶, our results suggest that SMARCAL1 F446A, which does not interact with RAD51,
299 might display a defective fork reversal activity in mammalian cells.

300

301 **High concentrations of RAD51 protect DNA from degradation by MRE11, EXO1 and DNA2 nu-** 302 **cleases**

303 In homologous recombination, the processing of DSBs is initiated by short-range resection that involves
304 the endo- and exonuclease activities of MRN and CtIP, followed by the long-range pathways catalyzed
305 by EXO1 and/or DNA2-BLM/WRN^{4, 5, 60}. The same nucleolytic pathways were shown to degrade nas-
306 cent DNA at stalled replication forks, with relative contributions of the nucleases dependent on condi-
307 tions and genetic background^{9, 27, 30, 32, 34, 35}. To investigate the function of RAD51 in DNA protection,
308 we reconstituted DNA end resection reactions without or with various concentrations of RAD51. We
309 observed that RAD51 inhibited all DNA end resection reactions tested, including the exonuclease ac-
310 tivity of MRE11-RAD50, the endonuclease of MRE11-RAD50-NBS1 in conjunction with phosphory-
311 lated CtIP (Fig. 5a-e), and the long-range pathways of EXO1 and DNA2-WRN (Fig 5f-k). These ex-
312 periments allowed us to make several conclusions.

313 First, higher RAD51 concentrations were in general required for DNA protection compared to motor-
314 driven strand annealing. Approximately 300 nM to low micromolar RAD51 was required for a robust
315 protection against nucleolytic degradation, depending on the substrate and the respective nuclease ana-
316 lyzed. The RAD51 concentrations required for the inhibition of the endonuclease of MRN-CtIP were
317 similar to those required to inhibit the nonspecific NspI endonuclease, which may be used as a read-out
318 for RAD51 filament formation (Fig. 5a, b and Supplementary Fig. 5a). These results suggest that effi-
319 cient inhibition of DNA end resection occurs under conditions permissive for stable RAD51 filament
320 formation.

321 Second, the DNA affinity of RAD51 directly corresponds to its efficacy in inhibiting DNA degradation.
322 To this point, we used the RAD51 variants that differ in their capacity to bind DNA^{61, 62, 63}. The tightly
323 binding RAD51-KR mutant generally inhibited resection more efficiently than wild type RAD51, while
324 the poorly DNA binding RAD51 variants KA, YA and TP were largely deficient in protection (Fig. 5a-
325 d, h, i). Furthermore, the affinity of RAD51 to DNA depends on the presence of ATP. ATP binding
326 stimulates DNA binding by RAD51, while ATP hydrolysis leads to RAD51 dissociation from DNA⁶¹.
327 Correspondingly, the highest DNA binding affinity of RAD51 is observed in buffers with the non-
328 hydrolysable ATP analog ATP- γ -S. In accord with the modulation of DNA binding affinity of RAD51
329 by the nucleotide co-factors, we observed the strongest DNA protection by RAD51 when reactions
330 contained ATP- γ -S, followed by ATP, and the weakest protection in reactions lacking ATP (Fig. 5e-g).
331 These latter experiments could only be performed with resection nucleases that do not require ATP,
332 such as the exonuclease of MR and the exonuclease of EXO1.

333 Third, we did not find any apparent specific functional interactions between RAD51 and the DNA end
334 resection nucleases. To this point, we compared the capacity of human and yeast RAD51/Rad51 to
335 protect DNA against the human and yeast resection nucleases and nuclease complexes (Supplementary
336 Fig. 5b-h). We observed that human RAD51 was generally more efficient than yeast Rad51, which may
337 suggest some degree of specificity. However, human RAD51 was also more efficient in protecting DNA
338 against non-specific nucleases Exo-III and NspI (Supplementary Fig 5i, j). These experiments sug-
339 gested that the higher efficacy of human RAD51 compared to yeast Rad51 to protect DNA is not due
340 to specific functional interactions between human RAD51 and the nuclease complexes, but may be
341 rather due to a higher DNA affinity or protection capacity of human RAD51 *per se*.

342

343 **The function of RAD51 in DNA protection corresponds to its capacity to bind double-stranded** 344 **DNA**

345 BRCA2 is required for nascent DNA protection by RAD51. Interestingly, the regions of BRCA2 re-
346 quired for DNA protection are distinct from those needed for homologous recombination and RAD51
347 loading onto RPA-coated ssDNA⁹. The BRCA2 BRC repeats are needed for homologous

348 recombination, and in biochemical assays they were shown to enhance the binding of RAD51 to RPA-
349 coated ssDNA, while they reduce the capacity of RAD51 to bind dsDNA^{9, 64, 65}. The BRC repeats are
350 however not involved in DNA protection upon replication stress. Rather, the C-terminal RAD51 bind-
351 ing site is required for DNA protection⁹. The biochemistry of the C-terminal site is less understood, but
352 it was demonstrated that it facilitates RAD51 binding also to dsDNA⁶⁶. These results prompted us to
353 investigate whether RAD51 binding to ssDNA overhangs at DNA ends, as indicated in current mod-
354 els¹⁶, indeed explains its protection function.

355 To investigate whether RAD51 binding to ssDNA or dsDNA explains its function in DNA protection,
356 we prepared blunt-ended, 5'-overhanged and 3'-overhanged substrates. The MR exonuclease was inhib-
357 ited by RAD51 to the same extent irrespectively of the presence of the overhang (Fig. 6a, b). This
358 showed that the overhang is not required to assure protection against MRE11, and infers that the pro-
359 tection is instead dependent on RAD51 binding to the dsDNA part of the substrate. The same result was
360 observed with EXO1. Although EXO1 shows a clear preference to process 5'-recessed strands and is
361 least efficient on 5'-overhangs⁶⁷, RAD51 inhibited DNA degradation to a similar extent with all struc-
362 tures tested (Fig. 6c, d), suggesting that overhang is not needed for protection. Likewise, the MRN-CtIP
363 endonuclease clips dsDNA, and we showed that a variety of protein blocks promote such activity, as
364 long as the blocks are located at DNA ends or DNA overhangs. Our observation that RAD51 blocks
365 the MRN-CtIP endonuclease (Fig. 5a, b) again suggests that the inhibitory function is caused by RAD51
366 binding to dsDNA. Together, these results demonstrate that the binding of RAD51 to dsDNA is respon-
367 sible for its inhibitory effect on the resection nucleases, at least *in vitro*. We show that the function of
368 RAD51 to protect DNA from nucleolytic degradation is structural, and directly corresponds to the af-
369 finity of RAD51 to bind dsDNA. Tightly-bound RAD51 filaments then serve as a non-specific barrier
370 against DNA degradation. Our results challenge the current model suggesting that the binding of
371 RAD51 to ssDNA overhangs at the apex of the reversed fork structure explains its function in protec-
372 tion^{16, 27, 67}. Our data instead suggest that the capacity of RAD51 to bind dsDNA is relevant for its
373 function in DNA protection, which is ultimately responsible for the maintenance of genome stability
374 during replication stress (Fig. 7).

375

376 **DISCUSSION**

377 Here we used biochemistry to study the function of the replication fork remodelers SMARCAL1,
378 ZRANB3 and HLTF, their regulation by RAD51 and RAD51 paralogs, as well the interplay of RAD51
379 with nucleases implicated in pathological DNA degradation upon replication stress.

380

381 **SMARCAL1, ZRANB3 and HLTF have non-redundant activities**

382 Depletion of either SMARCAL1, ZRANB3 or HLTF brings about a profound defect in replication fork
383 reversal, as observed by electron microscopy, or by proxy methods scoring for e.g., nascent DNA deg-
384 radation in various genetic backgrounds upon stress^{19, 22, 40, 41, 68, 69}. To better define the function of fork
385 remodelers, we compared here the specific activities of the fork remodelers on various substrates mim-
386 icking elements of fork reversal. We observed that SMARCAL1, but not ZRANB3 or HLTF, has a
387 unique capacity to anneal RPA-coated ssDNA, a function reminiscent of the RAD52 protein family.
388 The annealing function of SMARCAL1 depends on the RPA interaction motif within the N-terminus
389 of SMARCAL1. We hypothesize that such annealing function might be relevant during the initial an-
390 nealing of the displaced daughter strands during the early steps of fork reversal. The annealing activity
391 of SMARCAL1, similarly to RAD52, does not involve ATPase activity. Previously, the function of
392 SMARCAL1 and ZRANB3 was monitored in assays scoring for the annealing of bubbled DNA within
393 circular plasmid. Such activity, in contrast to annealing of RPA-coated ssDNA oligonucleotides, is de-
394 pendent on the motor activities of the remodelers. We show that in contrast to SMARCAL1 and
395 ZRANB3, which had similar activities, HLTF was largely inactive in this assay.

396 Using oligonucleotide-based substrates mimicking fork reversal, it has been previously reported that
397 SMARCAL1 and ZRANB3 have opposing preferences with respect to whether RPA is located on the
398 leading or the lagging DNA strand⁴². We show that in contrast, the activity of HLTF does not appear to
399 be affected by RPA. In branch migration, using 4-way junction substrates without ssDNA, HLTF and
400 ZRANB3 were the most active enzymes, while SMARCAL1 was the least efficient. Our experiments
401 demonstrated that the fork remodelers possess quite different specific activities with respect to the sub-
402 strates used. The data support model where fork remodeling is not catalyzed by a single enzyme in a
403 processive manner, but it is rather a process with various remodelers acting in a distributive manner,
404 depending on the nature of the DNA intermediate and the substrate preference of the respective remodel-
405 er. Such model would explain the non-redundant relationship of remodeler in fork reversal^{36, 69, 70}.

406

407 **Novel biochemical functions for RAD51 and the paralog complex BCDX2 in promoting DNA** 408 **translocases**

409 Previous cellular data suggested that RAD51 and the BCDX2 complex promote fork reversal, but the
410 underlying mechanism was not clear^{17, 39}. The function of RAD51 in fork remodeling was shown to be
411 genetically separable and thus different from its canonical role in homologous recombination. Specifi-
412 cally, the strand exchange function of RAD51 was dispensable, pointing at a potential structural func-
413 tion³⁸. We show here that RAD51 and the RAD51 BCDX2 paralog complex stimulate the strand an-
414 nealing and branch migration activities of SMARCAL1 and ZRANB3, two of the key enzymes impli-
415 cated in fork reversal. SMARCAL1 and ZRANB3 were stimulated when RAD51 concentration was
416 too low to support a nucleoprotein filament formation.

417 In accord with a recent cellular study that identified a function of BCDX2 in promoting fork reversal³⁹,
418 we find that the paralogs complex also directly stimulates SMARCAL1 and ZRANB3. Unexpectedly,
419 RAD51 and BCDX2 stimulated SMARCAL1 and ZRANB3 independently of each other, as we ob-
420 served mostly additive effects when combined. The function of the RAD51 paralogs, such as the
421 BCDX2 complex, in homologous recombination remains poorly defined. Some reports suggest a joint
422 function for the paralogs and RAD51. Specifically, BCDX2 was shown to have a classical recombina-
423 tion mediator function to load RAD51 on RPA-coated ssDNA⁶ to remodel RAD51 filaments for acti-
424 vation⁷¹, or to make them more resistant against disruption⁷². However, RAD51-independent function
425 of the RAD51 paralogs were also identified in cellular studies, such as in the single-strand annealing
426 pathway of DSB repair⁷³, and BCDX2 was also found to physically and functionally associate with the
427 HELQ helicase⁷⁴. The function of BCDX2 to promote SMARCAL1/ZRANB3 described here *in vitro*
428 also does not require RAD51.

429

430 **The interplay of RAD51 and paralogs in promoting SMARCAL1 and ZRANB3 involves physical** 431 **interactions**

432 RAD51 and BCDX2 did not stimulate HLTF, a third enzyme shown to catalyze fork reversal, suggest-
433 ing a specificity in the interplay of SMARCAL1 and ZRANB3 with RAD51 and BCDX2. In accord,
434 we found that RAD51 and BCDX2 physically interact with SMARCAL1 and ZRANB3. We could then
435 map the RAD51 interaction site in SMARCAL1 and constructed a single point mutant (SMARCAL1-
436 F446A) that disrupted the physical interaction with RAD51. The SMARCAL1 mutant was not impaired
437 in its activities *per se*, but was deficient in promoting nascent DNA degradation in BRCA1-deficient
438 cells, a process that requires the fork reversal activity of SMARCAL1, supporting the idea that the
439 identified interplay of SMARCAL1 and RAD51 is physiologically relevant.

440

441 **The function of RAD51 in DNA protection is largely non-specific**

442 Downstream of fork reversal, RAD51 protects nascent DNA from degradation against nucleases. We
443 reconstituted both the endo- and exonuclease activities of MRE11, as well as EXO1 and DNA2, which
444 were all implicated in nascent DNA degradation, depending on the cellular background. We then tested
445 for the effect of RAD51 on the individual nucleolytic pathways and observed that RAD51 inhibited
446 them all to a similar extent. The level of inhibition was comparable when we used other non-cognate
447 yeast or bacterial nucleases. Interestingly, human RAD51 was somewhat more efficient in DNA pro-
448 tection compared to yeast Rad51, but this difference was observed in conjunction with both the cognate
449 human as well as with the non-specific nucleases, suggesting that there is no apparent functional inter-
450 action between RAD51 and the resection nucleases. RAD51 therefore inhibits DNA degradation in a

451 largely non-specific manner, as a physical barrier on DNA. The concentrations of RAD51 required for
452 DNA protection were higher than those promoting fork remodeling, in accord with cellular data⁷⁵. DNA
453 protection assays with RAD51 and non-specific nucleases are used as a proxy for RAD51 filament
454 formation. Therefore, we conclude that RAD51 filament formation is likely prerequisite for DNA pro-
455 tection.

456

457 **RAD51 protects nascent DNA upon binding to dsDNA**

458 Contrary to current models, we provide evidence that the binding of RAD51 to dsDNA (as opposed to
459 ssDNA) may be crucial for its function in DNA protection (Fig. 7). Eukaryotic RAD51 has a similar
460 affinity to both ssDNA and dsDNA^{61, 76, 77}. In homologous recombination, RAD51 needs to bind ssDNA
461 to form an active nucleoprotein filament. The binding of RAD51 to dsDNA is instead inhibitory, and
462 several recombination factors facilitate RAD51 binding specifically to ssDNA^{57, 65, 77, 78}. The physiolog-
463 ical relevance of the high affinity RAD51 binding to dsDNA is not known. The strong dsDNA binding
464 capacity of eukaryotic RAD51 is somewhat paradoxical, because *E. coli*'s RecA binds preferentially to
465 ssDNA, demonstrating that stable dsDNA binding is not strictly associated with DNA strand exchange
466 activity^{77, 78}. Because of the recombination paradigm, but largely without direct evidence, it has been
467 assumed that RAD51 binding to ssDNA at the apex of the reversed fork is responsible for DNA pro-
468 tection^{16, 27}. Our data challenge this model, and instead suggest that RAD51 binding to the dsDNA part
469 of the reversed fork is primarily responsible for its protection capacity.

470 We showed that the MRE11-RAD50 or EXO1 exonucleases were inhibited by RAD51 to a similar
471 extent when using blunt-ended dsDNA or overhanged substrates, demonstrating directly that the pres-
472 ence of the overhang was not relevant for protection, at least in the reconstituted assay. RAD51 binding
473 to dsDNA also fully explains its protective function against the MRN-CtIP endonuclease ensemble.
474 MRN-CtIP only nicks dsDNA, even on overhanged substrates^{3, 79}. Binding of proteins to overhangs,
475 including non-cognate factors such as streptavidin, is not inhibitory for MRN-CtIP⁷⁹. RAD51 however
476 clearly inhibits the MRN-CtIP endonuclease when using blunt-ended dsDNA, suggesting that dsDNA
477 is the relevant substrate for RAD51 binding with respect to its protective function. We therefore propose
478 that RAD51 inhibits the resection nucleases due to its binding to dsDNA. This model better explains
479 the protective function of RAD51 *in vivo*, as it applies for reversed forks with any type of DNA structure
480 at the end of the reversed arm, and does not rely on the presence of an overhang to mediate DNA
481 protection. Electron microscopy analyses revealed that the regressed arms of the reversed forks are
482 mostly composed of dsDNA, irrespectively of the conditions tested¹⁷. Cell-based assays further indi-
483 cated that fork degradation can reach multiple kilobases in length, which goes beyond the length of the
484 regressed arm of the reversed fork^{17, 31}. Therefore, dsDNA is clearly being degraded at challenged rep-
485 lication forks, and RAD51 is involved in its protection.

486 One of the best-known co-factors of RAD51 in DNA protection is BRCA2. BRCA2 functions as a
487 recombination mediator in homologous recombination to load RAD51 on RPA-coated ssDNA, and
488 additionally has the capacity to channel RAD51 to ssDNA away from dsDNA^{64, 65}. This particular pro-
489 recombination function depends on the BRC repeats of BRCA2, and could be largely recapitulated with
490 only the short BRC4 peptide⁶⁵. However, the BRC repeats of BRCA2, despite being essential for ho-
491 mologous recombination, are dispensable for fork protection⁹. Instead, the protective function of
492 BRCA2 depends on its C-terminal RAD51 binding site⁹. Strikingly, this site was previously demon-
493 strated to strongly facilitate RAD51 binding to dsDNA⁶⁶. How the site affects ssDNA versus dsDNA
494 binding is not known. The capacity of the BRCA2 C-terminus to promote RAD51 binding to dsDNA
495 thus also agrees with our direct observation that RAD51 binding to dsDNA is critical for DNA protec-
496 tion *in vitro*. A number of additional factors including BRCA1 are also required for DNA protection⁸⁰.
497 Whether they affect RAD51 binding to dsDNA, or facilitate DNA protection because of a different
498 mechanism, such as upon RAD51-independent DNA binding or through a direct inhibition of the nu-
499 cleases, remains an interesting area of investigation for future studies. Together, our data suggest that
500 the dsDNA binding capacity of RAD51 may have evolved in conjunction with its function to prevent
501 pathological DNA degradation at the replication fork.

502

503 **Materials and Methods**

504

505 **Cloning, expression and purification of recombinant proteins**

506

507 **Human SMARCAL1, ZRANB3.** Recombinant FLAG-SMARCAL1, FLAG-ZRANB3 and their var-
508 iants were expressed in insect *Spodoptera frugiperda* 9 (*Sf9*) cells and purified by affinity chromatog-
509 raphy, using pFastBac-FLAG-SMARCAL1 and pFastBac-FLAG-ZRANB3 expression constructs²².
510 Point mutagenesis of the corresponding DNA sequences was carried out by QuikChange II site-directed
511 mutagenesis kit (Agilent Technologies), and the proteins were expressed and purified similarly as the
512 wild type counterparts. Primers used for cloning and mutagenesis are listed in [Table S1](#).

513

514 **Human HLTF.** The HLTF sequence was codon-optimized for *Sf9* insect cells and synthesized by Syn-
515 bio Technologies, and cloned using NheI and XmaI sites (New England Biolabs) into pFB-2xMBP-
516 CtIP-His⁸¹ to create pFB-2xMBP-HLTFco-His, replacing the CtIP sequence with that of HLTF. The
517 bacmids and baculoviruses were prepared according to manufacturer's instructions (Bac-to-Bac system,
518 Life Technologies). *Sf9* cells were transfected using a Trans-IT insect reagent (Mirus Bio). For protein
519 production, *Sf9* insect cells were seeded at 0.5×10^6 cells per ml 16 hours before infection. The cells
520 were then infected with respective baculoviruses and incubated for 52 hours at 27 °C with constant
521 agitation. Cells were harvested (500 g, 10 minutes) and washed once with ice cold Phosphate buffer
522 saline (PBS). The cell pellets were snap frozen in liquid nitrogen and stored at -80 °C. All the subse-
523 quent steps were carried out on ice or at 4 °C. The pellets were resuspended and incubated for 20
524 minutes with continuous stirring in 3-volumes of lysis buffer (50 mM Tris-HCl pH 7.5, 1 mM dithio-
525 threitol [DTT], 5 mM beta-mercaptoethanol [β -ME], 1 mM phenylmethylsulfonyl fluoride [PMSF],
526 1:400 [v/v] protease inhibitor cocktail [Sigma, P8340], 30 μ g/ml leupeptin [Merck]). Next, 50% glyc-
527 erol was added to reach a final concentration of ~16% to the cell extract, followed by 6.5% volume of
528 5 M NaCl (final concentration 305 mM), and further incubated for 30 minutes with continuous stirring.
529 The cell suspension was centrifuged for 30 minutes at 48,000 g to obtain soluble extract. The superna-
530 tant was transferred to tubes containing pre-equilibrated amylose resin (New England Biolabs, 4 ml per
531 liter of *Sf9* culture) and incubated for 1 hour with continuous rotation. The resin was collected by spin-
532 ning at 2,000 g for 2 minutes and washed extensively batch-wise and also on a disposable 10 ml column
533 (ThermoFisher) with amylose wash buffer (50 mM Tris-HCl pH 7.5, 5 mM β -ME, 1 mM PMSF, 10%
534 glycerol, 1 M NaCl). The final wash was performed at 300 mM NaCl. Protein was eluted with amylose
535 elution buffer (50 mM Tris-HCl pH 7.5, 5 mM β -ME, 1 mM PMSF, 10% glycerol, 300 mM NaCl, 10
536 mM maltose [Sigma]) and the total protein concentration was estimated by Bradford assay. To cleave
537 off the maltose-binding protein (MBP) tag, 1/6 (w/w) of PreScission Protease, with respect to total
538 protein concentration in the eluate, was added and incubated for 1 hour at 4 °C. The sample was then

539 supplemented with 10 mM imidazole and further passed through pre-equilibrated (amylose elution
540 buffer supplemented with 10 mM imidazole) Ni-NTA agarose resin (Qiagen) on a disposable column
541 for 1 hour in flow. The Ni-NTA resin was washed 4-times with Ni-NTA wash buffer (50 mM Tris-HCl
542 pH 7.5, 5 mM β -ME, 1 M NaCl, 10% glycerol, 1 mM PMSF, 40 mM imidazole). Prior to elution, the
543 protein was washed once with the same Ni-NTA wash buffer as above but with 150 mM NaCl. Protein
544 was eluted in the same buffer supplemented with 300 mM imidazole, and subsequently dialyzed (50
545 mM Tris-HCl pH 7.5, 5 mM β -ME, 100 mM NaCl, 10% glycerol, 0.5 mM PMSF), sub-aliquoted, snap
546 frozen and stored at -80 °C for later use.

547

548 **Human RAD51 paralogs BCDX2 and CX3.** Sequences for human RAD51 paralogs (RAD51B,
549 RAD51C, RAD51D, XRCC2 and XRCC3) were codon-optimized for expression in *Sf9* cells and syn-
550 thetized by Synbio Technologies. FLAG-RAD51B and 10xHis-RAD51C were cloned into a pFB dual
551 expression vector (ThermoFisher). The multiple cloning site 1 was utilized for FLAG-RAD51B using
552 BamHI and NotI cloning sites and the multiple cloning site 2 was used for 10xHis-RAD51C employing
553 the XmaI and NheI restriction sites, to create pFB-FLAG-RAD51Bco-10xHis-RAD51Cco. RAD51D
554 and XRCC2 were similarly cloned into the same sites, respectively, to obtain pFB-RAD51Dco-
555 XRCC2co. XRCC3 was synthesized as BamHI-FLAG-XRCC3-NotI and cloned into the above vector
556 to remove the RAD51B sequence to obtain pFB-FLAG-XRCC3co-10xHis-RAD51Cco. Baculoviruses
557 expressing RAD51B-RAD51C, RAD51D-XRCC2 and XRCC3-RAD51C were prepared separately
558 and *Sf9* cells were co-infected with optimized ratios for these viruses to express the BCDX2 complex
559 as a heterotetramer and the CX3 complex as a heterodimer. Both the complexes were purified in an
560 identical manner using affinity chromatography. Cells were harvested 52 hours post infection, washed
561 once with cold PBS, and the pellets were frozen in liquid nitrogen and stored at -80 °C until further use.
562 The subsequent steps were carried out on ice or at 4 °C. The cell pellet was resuspended in lysis buffer
563 (50 mM Tris-HCl pH 7.5, 2 mM β -ME, 1:400 [v/v] protease inhibitor cocktail [Sigma], 1 mM PMSF,
564 30 μ g/ml leupeptin (Merck), 20 mM imidazole) for 20 minutes. Then, 50% glycerol was added to a
565 final concentration of ~16%, followed by 5 M NaCl to a final concentration of 305 mM. The suspension
566 was incubated for additional 30 minutes with gentle agitation. The total cell extract was centrifuged at
567 48,000 g for 30 minutes to obtain soluble extract. The extract was then bound to Ni-NTA resin (Qiagen)
568 for 1 hour batch wise followed by extensive washing with Ni-NTA wash buffer (50 mM Tris-HCl pH
569 7.5, 2 mM β -ME, 300 mM NaCl, 10 % glycerol, 1 mM PMSF, 10 μ g/ml leupeptin, 20 mM imidazole)
570 both batch wise and on a disposable column. The protein complexes were eluted by Ni-NTA elution
571 buffer (Ni-NTA wash buffer containing 300 mM imidazole). The eluates were diluted 1:6 with a dilu-
572 tion buffer (Ni-NTA elution buffer without imidazole and 0.5 mM β -ME) and bound to FLAG resin
573 (Sigma) pre-equilibrated with dilution buffer in flow with a total contact time of ~90 minutes. Protein
574 bound FLAG-resin was washed 3-times with FLAG wash buffer (50 mM Tris-HCl pH 7.5, 0.5 mM β -

575 ME, 150 mM NaCl, 10 % glycerol, 1 mM PMSF) and 2 times with the same buffer with 100 mM NaCl
576 before being eluted with a FLAG elution buffer (FLAG wash buffer with 100 mM NaCl and 150 ng/μl
577 3xFLAG peptide [Sigma]). Complexes were sub-aliquoted, snap frozen and stored at -80 °C for later
578 use.

579

580 ***Drosophila* Topoisomerase I.** To prepare N-terminally truncated *Drosophila* topoisomerase I (catalytic
581 subunit) with 6xHis tag on its C-terminus, the ND423 plasmid (a kind gift from James T. Kadonaga,
582 University of California, San Diego, USA), was transformed in BL21 (DE3) pLysS cells and protein
583 was purified by nickel affinity chromatography⁸². The cell pellet from 1 liter culture was resuspended
584 and sonicated in lysis buffer (50 mM Tris-HCl pH 7.5, 1 mM PMSF, 500 mM NaCl, 10% glycerol, 2
585 mM β-ME, 10 μg/ml leupeptin, 20 mM imidazole) and supplemented with 1:400 protease inhibitor
586 cocktail (Sigma). Soluble extract was obtained by centrifugation at 48,000 g for 30 minutes and was
587 incubated with pre-equilibrated Ni-NTA resin for 2 hours at 4 °C. Next, resin was washed 4 times with
588 Ni-NTA wash buffer (50 mM Tris-HCl pH 7.5, 1 mM PMSF, 500 mM NaCl, 10% glycerol, 2 mM β-
589 ME, 20 mM imidazole). Before elution the resin was washed once with the same Ni-NTA wash buffer
590 as above but with 100 mM NaCl. Protein was eluted with elution buffer (50 mM Tris-HCl pH 7.5, 1
591 mM PMSF, 100 mM NaCl, 10% glycerol, 0.5 mM β-ME, 300 mM imidazole, 10 μg/ml leupeptin).
592 Peak fractions were pooled and diluted 1:5 in dilution buffer (50 mM Tris-HCl pH 7.5, 0.5 mM β-ME,
593 100 mM NaCl, 10 % glycerol, 1 mM PMSF, 10 μg/ml leupeptin) and the sample was loaded onto pre-
594 equilibrated HiTrap S and HiTrap Heparin columns connected in tandem (GE Healthcare), and washed
595 with 20 ml of dilution buffer. The same buffer with a salt gradient up to 1 M NaCl was used to elute
596 the protein from the HiTrap Heparin column after the HiTrap S column was disconnected. Peak frac-
597 tions were pooled and dialyzed in dilution buffer for 2 hours. Protein was aliquoted, snap-frozen and
598 stored at -80 °C.

599

600 **Yeast Rad51 (yRad51).** The *Rad51* sequence from *S. cerevisiae* was codon-optimized for bacterial
601 expression and was purchased from GenScript. It was cloned into pMALT-P (a kind gift from the Kow-
602 alczykowski laboratory, UC Davis, USA) with BamHI and PstI restrictions sites. The construct codes
603 for Rad51 protein with a N-terminal MBP-tag separated from Rad51 by a PreScission protease site. The
604 plasmid was transformed into BL21 (DE3) pLysS cells, 0.2% glucose was used to supplement the cul-
605 ture medium. The cell pellet from 2 liters was resuspended and sonicated in Buffer A (50 mM Tris-HCl
606 pH 7.5, 1 mM PMSF, 500 mM NaCl, 1 mM DTT, 10% glycerol), supplemented with 1:500 protease
607 inhibitor cocktail (Sigma). Soluble extract was obtained by centrifugation, and was incubated with am-
608 ylose resin (New England Biolabs) at 4 °C for 1 hour in Buffer A containing 0.01% NP40. Extensive
609 washes were carried out with Buffer A with 1 M NaCl, and subsequently with Buffer A containing 300
610 mM NaCl without PMSF. MBP-Rad51 was eluted with 10 mM maltose in Buffer A and 300 mM NaCl.
611 Peak fractions were pooled, incubated with PreScission Protease for 1 hour at 4 °C (1:7; w/w), and

612 further diluted with 20 mM Tris-HCl pH 7.5 to reduce NaCl concentration to 150 mM NaCl (final).
613 The sample was loaded onto pre-equilibrated HiTrap Q HP column (GE Healthcare). Buffer R (20 mM
614 Tris-HCl pH 7.5, 1 mM EDTA, 0.5 mM DTT, 10% glycerol) with 150 mM NaCl was used to wash the
615 column. The same buffer R with a salt gradient up to 700 mM NaCl was used to elute the protein. Next,
616 peak fractions were pooled and dialyzed over-night in Buffer R with 100 mM NaCl and without EDTA.
617 Protein was aliquoted, snap-frozen and stored at -80 °C.

618 **Human RAD51.** The *RAD51* sequence was cloned from pTXB3-RAD51 construct⁵⁷ into pMALT-P
619 vector BamHI and PstI restriction sites, yielding N-terminal MBP tag, PreScission protease site and
620 RAD51. The mutants were created by site directed mutagenesis using QuikChange II site-directed mu-
621 tagenesis kit following manufacturer's protocol (Agilent). The oligonucleotides used for mutagenesis
622 are listed in supplementary [Table S1](#). The RAD51 protein variants were expressed in BL21 (DE3)
623 pLysS cells. Each culture was supplemented with 0.2% glucose, induced with 0.5 mM IPTG and grown
624 overnight at 18 °C. The cells were then pelleted at 2,500 g for 15 minutes at 4 °C, washed once with
625 STE buffer (10 mM Tris-HCl pH 8, 500 mM NaCl, 1 mM EDTA), snap-frozen and kept in -80 °C until
626 use. The pellets were then resuspended in lysis buffer (50 mM Tris-HCl pH 7.5, 1 mM PMSF, 1 mM
627 DTT, 10% glycerol, 500 mM NaCl, 1:500 protease inhibitor cocktail [Sigma]), sonicated and lysate
628 was clarified by centrifugation at 48,000 g for 30 minutes. Next, the lysate was incubated with amylose
629 resin for 1 hour batch-wise at 4 °C, washed first with wash buffer I (50 mM Tris-HCl pH 7.5, 1 mM
630 DTT, 10% glycerol, 1 M NaCl) and then with wash buffer II (50 mM Tris-HCl pH 7.5, 1 mM DTT,
631 10% glycerol, 300 mM NaCl) followed by elution with wash buffer II containing 10 mM maltose. To
632 cleave off the MBP tag, PreScission Protease was added to the eluate and incubated overnight at 4 °C
633 (1:5, w/w). Cleaved RAD51 eluate was diluted with 50 mM Tris-HCl pH 7.5 to lower the NaCl con-
634 centration to 150 mM. The eluate was then applied to a Hitrap Q column (GE Healthcare). The column
635 was washed sequentially with wash buffer III (20 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.5 mM DTT,
636 10% glycerol, 150 mM NaCl) and eluted with wash buffer III with 300 mM NaCl. The fractions con-
637 taining RAD51 were pooled and dialyzed in 20 mM Tris-HCl pH 7.5, 1 mM DTT, 20% glycerol and
638 100 mM NaCl overnight. The dialyzed protein was aliquoted, snap-frozen and stored at -80 °C. Wild
639 type RAD51 was prepared from 4 liters of culture and all other variants were prepared from 1 liter
640 cultures following the same purification procedure.

641 **Human RPA.** Recombinant human RPA was expressed from p11d-tRPA construct (a kind gift from
642 M. Wold, University of Iowa) in BL21 (DE3) pLysS cells. Bacterial culture was grown at 37 °C (200
643 RPM) until O.D. 600 = 0.6, induced with 0.4 mM IPTG, and shaken at 18 °C (200 RPM) overnight.
644 Bacterial pellet was obtained by centrifugation, washed once with SD Buffer (10 mM Tris pH 8.0, 150
645 mM NaCl, 1 mM EDTA), snap-frozen and stored at -80 °C. Cell lysis, followed by purification using
646 ÄKTA pure (GE Healthcare) using HiTrap Blue HP, HiTrap desalting and HiTrap Q chromatography
647 columns (all GE Healthcare)⁸³.

648 **Human mitochondrial single-stranded DNA binding protein (SSB).** Recombinant mitochondrial
649 SSB was expressed and purified from *E. coli* BL21 cells⁸⁴.

650 **Human DNA2 and WRN.** Recombinant DNA2 was expressed in *Sf9* insect cells and purified by af-
651 finity chromatography by utilizing the N-terminal 6xHis and the C-terminal FLAG affinity tags⁸³. WRN
652 was purified by exploiting the maltose-binding protein (MBP) tag at the N-terminus and 10xHis tag at
653 the C-terminus. The MBP tag was cleaved off with PreScission Protease during purification. Detailed
654 procedures were described^{83, 84}.

655 **Human MRN, MR, MRE11, phosphorylated CtIP and EXO1.** Recombinant MRN (MRE11-
656 RAD50-NBS1) and MR (MRE11-RAD50) were purified as a complex from *Sf9* insect cells. Individual
657 baculoviruses coding for MRE11-6xHis, RAD50co-FLAG and NBS1co were prepared by standard la-
658 boratory procedures according to manufacturer's instructions (Bac-to-Bac, Life Technologies). De-
659 tailed procedures describing purification strategies have been described⁸³. Briefly, the purification in-
660 volved affinity chromatography using NiNTA agarose (Qiagen) and anti-FLAG affinity resin (Sigma).
661 Recombinant MRE11 alone was prepared using pFB-MBP-MRE11-His vector, using amylose resin,
662 PreScission Protease to remove the MBP tag, followed by affinity chromatography with NiNTA aga-
663 rose⁸⁵. Phosphorylated CtIP was purified from *Sf9* cells using amylose and NiNTA resins³. The recom-
664 binant human *EXO1* gene was expressed from pFB-EXO1-FLAG in *Sf9* insect cells by using the Bac-
665 to-Bac expression system (Invitrogen), according to manufacturer's recommendations. Protein purifi-
666 cation was performed with anti-FLAG (Sigma) affinity chromatography followed by HiTrap SP HP ion
667 exchange chromatography (GE Healthcare) utilizing ÄKTA pure (GE Healthcare)⁸⁶.

668 **Yeast MRX, Mre11, phosphorylated Sae2 and Exo1.** The proteins were prepared from *Sf9* insect
669 cells and purified using affinity and ion exchange chromatography^{87, 88, 89}. Exo1 was prepared according
670 to an established procedure⁶⁷.

671 **Preparation of oligonucleotide-based DNA substrates.**

672 Oligonucleotides were either 5'-end-labeled with [γ -³²P]-ATP (Perkin Elmer) and T4 polynucleotide
673 kinase (NEB), or 3'-end-labeled with [α -³²P]-dCTP (Perkin Elmer) and terminal transferase (NEB) en-
674 zymes, respectively. The labeled DNA was then purified on a Micro Bio-Spin P-30 Tris chromatog-
675 raphy columns (Bio-Rad)⁹⁰. Sequences for all oligonucleotides used to obtain the DNA substrates are
676 listed in supplementary [Table S1](#).

677 Branch migration substrate was prepared as described previously⁹¹. Briefly, 5'- or 3'-end-labeled 2 μ M
678 XO1 was mixed with 2.4 μ M XO2 (1:1.2 ratio) in annealing buffer (10 mM Tris-HCl pH 8, 50 mM
679 NaCl, 10 mM MgCl₂). In parallel, 2 μ M each (1:1 ratio) of XO1c.MM2 and XO2c.MM oligonucleotides
680 were similarly combined. The respective mixes were heated for 3 minutes at 95 °C and slowly cooled
681 down to room temperature overnight. The two respective samples were then combined and annealed

682 together (37 °C for 30 minutes), followed by gradual cooling down to room temperature (2 hours).
683 Substrate was then stored at -20 °C until further use.
684 Fork reversal substrates were prepared as described earlier⁴². Briefly, to create a fork with a leading
685 strand gap, 3'- or 5'-labeled nascent #DC-6 (100 nM final) was annealed with unlabeled parental #DC-
686 2 (120 nM final) in annealing buffer (as above) by heating (3 minutes at 95 °C) and gradually cooled
687 down to room temperature overnight. Similarly, the complementary half comprising of unlabeled pa-
688 rental #DC-1 (180 nM final) and unlabeled nascent #DC-4 (180 nM final) were separately annealed.
689 These two corresponding halves (#DC-6 + #DC-2 and #DC-1 + #DC-4) were then combined and an-
690 nealed at 37 °C for 45 minutes and then cooled down to room temperature during 2 hours, and stored
691 at -20 °C until further use. To create a fork with a lagging strand gap, 3'- or 5'-labeled nascent #DC-3
692 (100 nM final) was annealed with unlabeled parental #DC-1 (120 nM final) and the corresponding half
693 containing unlabeled parental #DC-2 (150 nM final) was annealed with unlabeled nascent #DC-5 (150
694 nM final) oligos. These two halves (#DC-3 + #DC-1 and #DC-2 + #DC-5) were then combined and
695 annealed as above.
696 To prepare the 5'-labeled 70 bp-long dsDNA substrate, which was quadruple blocked with streptavidin,
697 the oligonucleotides PC210 and PC211 were used⁸⁹. To prepare 5'-labeled 50 bp-long dsDNA, oligo-
698 nucleotides X12-3 and X12-4C were annealed. To prepare 5'-overhang substrate, X12-3 and X12-4SC
699 were annealed, creating a structure with 19 nt-long 5'-overhang and 31 base pairs of dsDNA. To prepare
700 3'-overhang substrate, X12-3SC + X12-4NC were annealed, creating a structure with 19 nt-long 3'-
701 overhang and 31 base pairs of dsDNA, as described⁹².

702

703 **Topoisomerase-coupled annealing assays**

704 The bubbled DNA annealing assay was performed as described⁴³ with the following modifications.
705 pBluescript II KS (+) plasmid (a kind gift from Marcus Thelen, IRB, Bellinzona, Switzerland) was used
706 as a substrate. 100 ng supercoiled DNA was mixed with 1 µg RPA in TE pH 8.0 in 10 µl volume, and
707 incubated for 45 minutes at 37 °C. Next, 16.5 nM (final) of catalytic domain of *Drosophila* topoi-
708 somerase I was added to the reaction mixture and incubated for additional 10 minutes at 37 °C. Next,
709 annealing buffer (20 mM Tris-HCl pH 7.5, 5 mM MgCl₂, 1 mM DTT, 0.2 mg/ml BSA, 100 mM NaCl),
710 2.5 mM ATP (final) and corresponding amounts of proteins (as indicated in figures) or protein storage
711 buffer were added. The final volume was adjusted to 20 µl with water and the reactions were incubated
712 for 30 minutes at 37 °C. The reactions were terminated by adding 2.5 µl of 5 M NaCl at room temper-
713 ature for 2 minutes, followed by 6.5 µl of 2% stop buffer (100 mM Tris-HCl pH 7.5, 150 mM EDTA,
714 2% SDS [w/v], 30% glycerol, 0.1% bromophenol blue) and 1 µl Proteinase K (20 mg/ml, Roche), and
715 incubated 10 minutes at 37 °C. The mixture was resolved by 1% agarose gel electrophoresis in 1x TAE
716 buffer, and DNA was visualized by post-staining with GelRed (Biotium) according to manufacturer's

717 instructions. The gels were then imaged (InGenius3, GeneSys) and quantitated as the fraction of near
718 or fully relaxed DNA using Image J. Graphs were generated by GraphPad Prism software.

719 **Fork reversal and branch migration assays**

720 The assays were carried out in a reaction buffer containing 20 mM Tris-HCl pH 7.5, 5 mM MgCl₂, 1
721 mM DTT, 0.1 mg/ml BSA, 10% glycerol, 2.5 mM ATP (unless indicated otherwise), and 1 nM (fork
722 reversal) or 0.5 nM (branch migration) DNA substrate, with 150 mM NaCl (unless indicated otherwise).
723 Master-mixes were prepared on ice and where indicated, RPA (3 nM) was added to the master-mix for
724 15 minutes on ice. 13 µl reaction mixture was then dispersed to individual tubes and supplemented with
725 other recombinant proteins (as indicated) and final volume was adjusted to 15 µl with protein storage
726 buffer. The reactions were continued for additional 30 minutes at 37 °C and terminated by the addition
727 of 5 µl stop buffer (100 mM Tris-HCl pH 7.5, 150 mM EDTA, 0.2% SDS [w/v], 30% glycerol, 0.1%
728 bromophenol blue) and 1 µl Proteinase K (20 mg/ml, Roche) and incubated for 10 minutes at 37 °C.
729 Samples were loaded onto 8% polyacrylamide (19:1 acrylamide:bisacrylamide) gels in 1x Tris-borate-
730 EDTA (TBE) (BIO-RAD Mini-PROTEAN system, 1 mm thick) and separated for 60 minutes at 80 V
731 at room temperature. The gels were dried using a BIO-RAD gel drier on 17 CHR paper (Whatman),
732 and were exposed to storage phosphor screens and scanned using Typhoon FLA 9500 (GE Healthcare)
733 phosphor imager. The gels were quantitated with ImageJ. Graphs were generated by GraphPad Prism
734 software.

735

736 **Single-stranded DNA annealing assay**

737 DNA annealing reactions were carried out at 37 °C for the times indicated using complementary oligo-
738 nucleotides X12-3 and X12-4C (please see supplementary Table S1 for sequences), 1 nM each. The
739 X12-3 oligonucleotide was labeled at the 5'-end. Control reactions were supplemented with protein
740 storage buffer. Reaction master mixes were prepared separately with the respective ssDNA in a buffer
741 containing 25 mM Tris-acetate pH 7.5, 5 mM magnesium acetate, 1 mM DTT, 1 mM ATP and supple-
742 mented with 4 nM RPA or SSB where indicated. The two respective master mixes were then incubated
743 for 5 minutes at 37 °C to allow RPA or SSB binding. The two respective mixes containing complemen-
744 tary ssDNA were then combined. Motor proteins and cofactors (when indicated) were added immedi-
745 ately and reaction volume was adjusted with water. The reactions were then incubated at 37 °C; 15 µl
746 reaction mixture was withdrawn at the indicated time points into tubes containing 5 µl stop buffer (100
747 mM Tris-HCl pH 7.5, 150 mM EDTA, 0.2% SDS [w/v], 30% glycerol, 0.1% bromophenol blue) and 1
748 µl Proteinase K (20 mg/ml, Roche). Tubes were kept on ice until the collection of the last time point,
749 and finally transferred to 37 °C for 10 minutes to achieve deproteination. Samples were then loaded

750 onto 8% polyacrylamide (19:1 acrylamide:bisacrylamide) gels in 1x TBE (BIO-RAD Mini-PROTEAN
751 system, 1 mm thick), and processed as described above.

752

753 **ATPase assays**

754 ATPase assays were performed in a buffer containing 20 mM Tris-HCl pH 7.5, 5 mM MgCl₂, 1 mM
755 DTT, 0.1 mg/ml BSA, 10% glycerol, 100 mM NaCl (unless otherwise indicated in the figures), 100 nM
756 ATP, 1 nM of [γ -³²P] ATP (Perkin Elmer). 2961 bp long supercoiled pBluescript II KS (+) (7 nM, in
757 molecules) or 5 nM unlabeled fork (#DC-1 + #DC-2) or Holliday junction structures ([XO1+XO2]+
758 [XO1c.MM2 + XO2c.MM]) were used as a substrate. Recombinant proteins were added on ice and the
759 samples were incubated at 37 °C for 60 minutes. Reactions were stopped with 2 μ l of 0.5 M EDTA and
760 separated using TLC plates (Merk) and 0.3 M LiCl and 0.3 M formic acid as a mobile phase. Dried
761 plates were exposed to storage phosphor screens (GE Healthcare) and scanned by a Typhoon FLA 9500
762 phosphorimager (GE Healthcare). Signals were quantified using ImageJ software. Spontaneous ATP
763 hydrolysis signal (Pi) from no protein lanes were removed as a background and the fraction of ATP
764 hydrolysis was obtained as a normalized value. Graphs were generated by GraphPad Prism software.

765

766 **Electrophoretic mobility shift assays**

767 The electrophoretic mobility shift assay (EMSA) to characterize the binding of BCDX2 complex to 70-
768 mer ssDNA (PC210) or dsDNA (PC210 annealed with PC211), 1 nM final; was carried out in 15 μ l
769 volume in a binding buffer containing 20 mM Tris-acetate pH 7.5, 1 mM DTT, 1 mM magnesium
770 acetate, 0.1 mg/mL BSA (NEB) and 1 mM ATP. PC210 was labeled at 5' end. Reactions were assem-
771 bled on ice and supplemented with increasing concentrations of BCDX2, and incubated for 30 minutes
772 at 37 °C. The reactions were mixed with 5 μ l loading buffer (50% glycerol, 0.1 % bromophenol blue)
773 and loaded on 8% polyacrylamide (19:1 acrylamide:bisacrylamide) gels in 1x TBE (BIO-RAD Mini-
774 PROTEAN system, 1 mm thick), and separated for 150 minutes at 80 V at 4 °C. The gels were dried
775 using a BIO-RAD gel drier on 17 CHR paper (Whatman), exposed to storage phosphor screens and
776 scanned using Typhoon FLA 9500 (GE Healthcare) phosphor imager.

777

778 **Protein-protein interaction assays**

779 To study the interaction between SMARCAL1 wild type and corresponding SMARCAL1 F→A vari-
780 ants with RAD51 or between ZRANB3 WT, ZRANB3 F→A variants with RAD51, bacterial soluble
781 extract containing MBP-RAD51 was incubated with amylose resin (50 μ l, NEB). The resin was washed
782 with wash buffer I (25 mM Tris-HCl pH 7.5, 0.5 mM DTT, 3 mM EDTA, 100 mM NaCl, 0.2 μ g/ μ l

783 BSA) and incubated with recombinant purified FLAG-SMARCAL1, FLAG-ZRANB3 or the FLAG-
784 BCDX2 complex (all 1 µg) in 150 µl IP buffer (25 mM Tris-HCl pH 7.5, 0.5 mM DTT, 3 mM EDTA,
785 100 mM NaCl, 0.2 µg/µl BSA, 10% Glycerol) for 1 hour at 4 °C. The resin with bound proteins was
786 washed 5 times with 1 ml wash buffer III (25 mM Tris-HCl pH 7.5, 1 mM DTT, 3 mM EDTA, 100
787 mM NaCl, 0.05% Triton X-100), and eluted with wash buffer III (70 µl) containing 30 mM maltose
788 and Avidin (0.11 µg/µl) as a stabilizer. Samples were analyzed by Western blotting using anti-MBP
789 primary antibody (MBL, M091-3, 1:1000) against MBP-RAD51 and anti-FLAG primary antibody
790 (Sigma, F3165, 1:1000) against SMARCAL1, ZRANB3 or against RAD51B of the BCDX2 complex,
791 respectively, by standard procedures.

792 To study interaction between RAD51 and ZRANB3 variants, FLAG-tagged ZRANB3 variants were
793 expressed in *Sf9* cells, cells were lysed and soluble extract containing the FLAG-ZRANB3 proteins was
794 bound to M2 anti-FLAG affinity resin (50 µl, Sigma). The resin was washed 3-times with 1 ml wash
795 buffer I (25 mM Tris-HCl pH 7.5, 0.5 mM DTT, 3 mM EDTA, 100 mM NaCl, 0.2 µg/µl BSA) and
796 incubated for 1 hour at 4 °C with recombinant purified RAD51 (1 µg) in 150 µl IP buffer (25 mM Tris-
797 HCl pH 7.5, 0.5 mM DTT, 3 mM EDTA, 100 mM NaCl, 0.2 µg/µl BSA). The resin with bound proteins
798 was washed 5-times with 1 ml wash buffer II (25 mM Tris-HCl pH 7.5, 0.5 mM DTT, 3 mM EDTA,
799 100 mM NaCl, 0.1% NP40, 0.2 µg/µl BSA), and proteins were eluted with wash buffer II (70 µl) con-
800 taining 150 ng/µl 3xFLAG peptide (GLPBIO) and Avidin (0.11 µg/µl [Sigma]) as a stabilizer. Samples
801 were analyzed by Western blotting using anti-RAD51 primary antibody (Abcam-133534, 1:1000) or
802 by Ponceau staining to show ZRANB3, using standard laboratory procedures.

803 To study the interaction between ZRANB3 and the BCDX2 complex, or between SMARCAL1 variants
804 and the BCDX2 complex, 1 µg (1 µl) anti-His primary antibody (MBL-D2913) was mixed with 15 µl
805 Dynabeads Protein G (Invitrogen) slurry in a solution containing 150 µl 1X PBS containing 0.05%
806 Tween 20 (PBS-T). The mixture was incubated for 45 minutes at room temperature with gentle mixing.
807 The cocktail was washed 3 times with 150 µl PBS-T and was further resuspended in 60 µl IP buffer (25
808 mM Tris-HCl pH 7.5, 0.5 mM DTT, 3 mM EDTA, 100 mM NaCl, 0.2 µg/µl BSA), which was then
809 supplemented with 1 µg recombinant purified BCDX2 complex and incubated for 1 hour at 4 °C with
810 gentle mixing. The beads were washed 3-times with 150 µl wash buffer (50 mM Tris-HCl pH 7.5, 1
811 mM DTT, 3 mM EDTA, 100 mM NaCl, 0.05% Triton X-100) and again resuspended in IP buffer.
812 Purified recombinant SMARCAL1 or ZRANB3 (1 µg) was added and incubated for 1 hour at 4 °C with
813 gentle mixing, and washed 4-times with wash buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 0.05%
814 Triton X-100). Proteins were eluted by heating the beads for 3 minutes at 95 °C in 60 µl SDS buffer
815 (50 mM Tris-HCl pH 6.8, 1.6 % SDS, 10 % Glycerol, 10% DTT, 0.01 % Bromophenol Blue) and
816 transferred to a new tube containing Avidin as a stabilizer (0.11 µg/µl). Samples were resolved by
817 polyacrylamide gel electrophoresis and protein bands were visualized either by silver staining or by

818 Western blotting using anti-FLAG to detect SMARCAL1 and ZRANB3, and by anti-His primary anti-
819 bodies to detect RAD51C of the BCDX2 complex by standard procedures.

820

821 **Antibodies.** The antibodies used for Western blotting, immunoprecipitation and DNA fiber assay were
822 used as follows: Mouse anti-RAD51B (Santa Cruz sc-377192; 1:1,000 dilution for WB), Mouse anti-
823 XRCC2 (Santa Cruz sc-365854; 1:1,000 dilution for WB), Mouse anti-XRCC3 (Santa Cruz sc-271714;
824 1:1,000 dilution for WB), Rabbit anti-RAD51C (Abcam ab95069; 1:1,000 dilution for WB), Rabbit
825 anti-RAD51D (Abcam ab202063; 1:1,000 dilution for WB), Rat anti-BrdU (Abcam ab6326; 1:100 di-
826 lution for DNA fiber assay), Mouse anti-BrdU (Becton Dickinson BD347580; 1:100 dilution for DNA
827 fiber assay), Mouse anti-SMARCAL1 (Santa Cruz sc-376377; 1:1,000 dilution for WB), Mouse anti-
828 BRCA1 (Santa Cruz sc-6954; 1:100 dilution for WB), Rat anti-TUBULIN (Abcam ab-6160; 1:50,000
829 dilution for WB), Goat anti-mouse Alexa Fluor 488 (Thermo Fisher A-11029; 1:300 dilution for DNA
830 fiber assay), Goat anti-rabbit Alexa Fluor 594 (Thermo Fisher A-11008; 1:300 dilution for DNA fiber
831 assay), Mouse anti-his (MBL D291-3; 1 µg for pulldown assay), Mouse anti-FLAG (Sigma F3165;
832 1:2,000 dilution for WB), Mouse anti-MBP (MBL M091-3; 1:1,000 dilution for WB), Rabbit anti-
833 RAD51 (Abcam ab133534; 1:1,000 dilution for WB).

834

835 **Nuclease protection assays**

836 Endonuclease assays with MRN-pCtIP were performed in a 15 µl volume in a nuclease buffer (25 mM
837 Tris-HCl pH 7.5, 1 mM manganese acetate, 5 mM magnesium acetate, 1 mM DTT, 1 mM ATP, 0.25
838 mg/mL BSA, 1 mM phosphoenolpyruvate, 80 U/ml pyruvate kinase [Sigma]) with 1 nM biotinylated
839 DNA substrate (in molecules, 70 bp-long, 5'-end-labeled PC210 and PC211) and incubated with strep-
840 tavidin (15 nM, Sigma) for 5 minutes at room temperature to block the DNA ends. Before the addition
841 of nucleases, increasing amounts of yeast and human RAD51 were added to the reactions and preincu-
842 bated for 10 minutes at 37 °C. Recombinant MRN and pCtIP were subsequently added, and the reaction
843 was incubated for 2 hours at 37 °C. Endonuclease assays with yeast MRX-pSae2 were performed sim-
844 ilarly as MRN-pCtIP, however yeast and human RAD51 assembly (10 minutes incubation) and subse-
845 quent reactions were performed at 30 °C for 30 minutes.

846 Exonuclease assays with human MR were performed in the nuclease buffer as above, but with 5 nM
847 DNA substrate (in molecules, except where mentioned otherwise), which was 50 bp-long dsDNA (X12-
848 3 and X12-4C) or with a 3' (X12-3SC + X12-4NC) or 5' (X12-3 and X12-4SC) overhangs. Yeast and
849 human RAD51 were then preassembled for 10 minutes on DNA at 37 °C and the assays were subse-
850 quently incubated for 120 minutes at 37 °C after adding the nucleases. RAD51 assembly and subsequent
851 nuclease assays with yeast MR were performed at 30 °C.

852 For nuclease assays with MRE11, the reaction buffer contained 25 mM Tris-HCl pH 7.5, 3 mM man-
853 ganese acetate, 5 mM magnesium acetate, 1 mM DTT, 1 mM ATP, 0.25 mg/ml BSA, 1 mM phosphoe-
854 nolpyruvate and 80 U/ml pyruvate kinase (Sigma). 1 nM 5'-end-labeled 50 bp-long dsDNA (in mole-
855 cules, X12-3 and X12-4C) was used as a substrate. Human or yeast RAD51/Rad51 assembly (10
856 minutes) and further reactions were carried out at 37 °C for 120 minutes.

857 Nuclease assays with human EXO1 were performed with 1 nM 5'-end-labeled 50 bp-long dsDNA sub-
858 strate (in molecules, X12-3 and X12-4C) in a buffer with 25 mM Tris-HCl pH 7.5, 2 mM magnesium
859 acetate, 1 mM DTT, 1 mM ATP, 0.1 mg/ml BSA, 1 mM phosphoenolpyruvate and 80 U/ml pyruvate
860 kinase (Sigma). Human or yeast RAD51/Rad51 was assembled on DNA for 10 minutes at 37 °C and
861 the reactions were further incubated at 37 °C for 30 minutes. However, for assays with yeast Exo1, the
862 buffer contained 5 mM magnesium acetate and the reactions were performed at 30 °C.

863 Endonuclease assays with NspI (NEB) were performed with 1 nM (in molecules) 5'-end-labeled 50 bp-
864 long dsDNA (X12-3 and X12-4C) in CutSmart buffer (NEB) and supplemented with 2.5 mM ATP to
865 aid RAD51 binding to DNA. Substrates were preincubated with increasing amount of human or yeast
866 Rad51 for 10 minutes at 37 °C followed by the addition of 1 unit of NspI (per 15 µl) and further incu-
867 bation for 30 minutes at 37 °C.

868 EXO-III mediated Holliday junction degradation assay (0.5 nM 5'-end-labeled substrate, in molecules)
869 was performed in branch migration assay buffer containing 100 mM NaCl. However, in the assays
870 comparing the DNA protection by human and yeast RAD51/Rad51, 1 nM 5'-end-labeled 50 bp-long
871 dsDNA substrate was used in branch migration assay buffer without additional salt. RAD51 assembly
872 (10 minutes) and subsequent reactions (30 minutes) were performed at 37 °C.

873 All reactions were stopped with 0.5 µl EDTA (0.5 M) and 1 µl proteinase K (20 mg/ml, Roche), and
874 incubated at 50 °C for 30 minutes. An equal volume of formamide dye (95% [v/v] formamide, 20 mM
875 EDTA, 0.1% bromophenol blue) was added and the samples were heated at 95 °C for 4 minutes and
876 separated on 15% denaturing polyacrylamide gels (ratio acrylamide: bisacrylamide 19:1, Bio-Rad). The
877 gels were fixed for 30 minutes at room temperature (40% methanol, 10% acetic acid, 5% glycerol) and
878 dried on a 3 MM CHR paper (Whatman). The dried gels were exposed to storage phosphor screens (GE
879 Healthcare) and scanned by a Typhoon phosphor imager (FLA 9500, GE Healthcare). The gels were
880 quantitated with ImageJ. Graphs were generated by GraphPad Prism software.

881 For DNA2-catalyzed assays, randomly labeled 2.2-kbp-long substrate was prepared by amplifying the
882 human NBS1 gene by PCR from pFB-MBP-NBS1-his plasmid⁸⁵ using Phusion high-fidelity DNA pol-
883 ymerase (New England Biolabs) and the NBS1_F and NBS1_R primers (see [Table S1](#)). 66 nM [α -
884 ³²P]dCTP was added to the PCR reaction together with the standard dNTPs concentration (200 µM
885 each). The PCR reaction product was purified using the QIAquick PCR purification kit (Qiagen) and

886 Chroma Spin TE-200 columns (Clontech). Purified DNA was quantitated by comparing the radioactive
887 DNA fragment with known amounts of a cold PCR product on an agarose gel stained with GelRed
888 (Biotium). Nuclease assays with PCR-based DNA substrates⁸⁶ were performed in a 15 µl volume in a
889 reaction buffer containing 25 mM Tris-acetate pH 7.5, 2 mM magnesium acetate, 1 mM ATP, 1 mM
890 DTT, 0.1 mg/ml BSA, 1 mM phosphoenolpyruvate (PEP), 80 U/ml pyruvate kinase (Sigma), 50 mM
891 NaCl, RPA (176 nM) and 1 nM substrate (in molecules). Increasing amount of RAD51 (as indicated
892 in the figure) was preincubated with the substrates for 10 minutes at 37°C in the reaction buffer, which
893 was then supplemented with other recombinant proteins and the reaction was continued for 30 minutes
894 at 37 °C. Reactions were stopped with 5 µl 2% stop solution (150 mM EDTA, 2% sodium dodecyl
895 sulfate, 30% glycerol, 0.1% bromophenol blue) and 1 µl of proteinase K (20 mg/ml, Roche) and incu-
896 bated at 37°C for 10 minutes. Samples were resolved by 1% agarose gel electrophoresis. Gels were
897 dried on DE81 chromatography paper (Whatman), exposed to storage phosphor screens (GE
898 Healthcare) and scanned by a Typhoon 9500 phosphor imager (GE Healthcare). The gels were quanti-
899 tated with ImageJ. Graphs were generated by GraphPad Prism software.

900

901 **Cellular assays**

902 MCF10A cells were maintained in a 1:1 mixture of DMEM and Ham's F12 medium (Thermo Fisher
903 Scientific), supplemented with 5% horse serum (Thermo Fisher Scientific), 20 ng/ml human epidermal
904 growth factor (Peprotech), 100 ng/ml cholera toxin, 10 µg/ml insulin and 0.5 µg/ml hydrocortisone
905 (Sigma-Aldrich). The human embryonic kidney fibroblast cell line HEK293T was maintained in
906 DMEM supplemented with 10% Fetalgro bovine growth serum. Gateway LR recombination (Thermo
907 Fisher Scientific) was used to recombine pDONR223-SMARCAL1(F446A) with the lentiviral expres-
908 sion vector pHAGE-C-FLAG-HA-DEST⁹³. Recombinant lentiviruses were generated by cotransfect-
909 ing helper packaging vectors together with lentiviral vectors into HEK293T cells using the TransIT-
910 293 transfection reagent (Mirus Bio). Virus-containing supernatants were collected 48 hours after trans-
911 fection and utilized to infect MCF10A cells in the presence of 8 µg/ml polybrene. 48 hours after viral
912 addition, MCF10A cells were selected using 1 µg/ml puromycin for 3 days. To perform RNAi treat-
913 ments, MCF10A SMARCAL1 KO cells complemented with WT and F446A mutant SMARCAL1 were
914 transfected with control or BRCA1 siRNA (GE Dharmacon) using lipofectamine RNAiMAX (Thermo
915 Fisher Scientific) according to manufacturer's instructions and subjected to DNA fiber assays 3 days
916 after transfection. To analyze cell lysates by Western blotting, cells were collected by trypsinization
917 and lysed in SB lysis buffer (62.5 mM Tris-HCl pH 6.8, 1.25% SDS, 12% glycerol, 0.71 M [5%] β-
918 ME, 0.002% bromophenol blue). Whole cell extracts were sonicated and heated for 5 minutes at 95 °C.
919 Following gel electrophoresis and transfer of cell extracts onto nitrocellulose, membranes were incu-
920 bated for 1 hour or overnight in blocking buffer (5% milk in TBS + 0.1% Tween20). Membranes were

921 subsequently incubated with primary antibodies diluted in antibody blocking buffer for 2 hours at room
922 temperature or overnight at 4 °C. Detection was achieved using appropriate horseradish peroxidase
923 (HRP)-conjugated secondary antibodies. Anti-SMARCAL1 (1:1000, Santa Cruz Biotechnology), anti-
924 BRCA1 (1:100, Santa Cruz Biotechnology) and anti-TUBULIN (1:50000, Abcam) antibodies were
925 used in western blot experiments.

926

927 **Single-molecule analysis of DNA replication**

928 Exponentially growing MCF10A cells were pulse-labeled with 30 μM CldU (25 minutes), washed and
929 exposed to 150 μM IdU (35 minutes). After exposure to the second nucleotide analog, the cells were
930 washed again in warm 1x PBS and treated or not for 4 hours with hydroxyurea (HU, 2 mM, Sigma).
931 Labeled cells were trypsinized and resuspended in ice-cold PBS at 4×10^5 cells/ml. Two microliters of
932 this suspension were spotted onto a pre-cleaned glass slide and lysed with 10 μl of spreading buffer
933 (0.5% SDS in 200 mM Tris-HCl pH 7.4, 50 mM EDTA). After 6 minutes, the slides were tilted at 15°
934 relative to horizontal, allowing the DNA to spread. Slides were air-dried, fixed in methanol and acetic
935 acid (3:1) for 2 minutes, rehydrated in PBS for 10 minutes and denatured with 2.5 M HCl for 50 minutes
936 at room temperature. Slides were then rinsed in PBS and blocked in PBS + 0.1% Triton X-100 (PBS-
937 T) + 5% BSA for 1 hour at room temperature. Rat anti-BrdU (1:100, Abcam) and mouse anti-BrdU
938 (1:100, BD) were then applied to detect CldU and IdU, respectively. After 1 hour incubation, the slides
939 were washed in PBS and stained with Alexa Fluor 488-labeled goat anti-mouse IgG1 antibody and
940 Alexa Fluor 594-labeled goat anti-rat antibody (1:300 each, Thermo Fisher Scientific). Slides were
941 mounted in Prolong Gold Antifade (Thermo Fisher Scientific) and held at -20 °C. Replication tracks
942 were imaged on a Nikon Eclipse 90i microscope fitted with a PL Apo 40X/0.95 numerical aperture
943 (NA) objective and measured using ImageJ software. In each experiment, 100 or more dual-labeled
944 tracts were measured for fork degradation estimation.

945

946 **FUNDING**

947 This work was supported by the Swiss National Science Foundation [grant number 31003A_175444 to
948 PC]; European Research Council [grant number 681630 to PC]; Swiss Cancer League [grant number
949 KLS-4370-02-2018 to PC]; National Institutes of Health [grant numbers R01CA197774 and
950 R01CA227450 to AC].

951

952 **DATA AVAILABILITY**

953 All primary data is available in this manuscript, supplementary information or source data.

954

955 ACKNOWLEDGEMENT

956 We thank Massimo Lopes and Matteo Berti for sharing unpublished data and proving antibodies against
957 RAD51 paralogs, James T. Kadonaga for providing Topoisomerase I expression plasmid, Marcus The-
958 len for providing pBluescript II plasmid. We thank Elda Cannavo and Valentina Mengoli for comments
959 on the manuscript.

960

961 CONFLICT OF INTEREST

962 The authors declare that they have no conflict of interest.

963

964 AUTHOR CONTRIBUTIONS

965 S.H. performed most of the experiments, analyzed data, prepared figures. A.S. did some protection
966 assay with human RAD51. L.R. prepared RAD51. A.T. did *in vivo* studies with mutant SMARCAL1.
967 G.R., I.C., A.A. generated reagents for the study. R.A. performed preliminary protection experiments
968 with overhanged substrates. A.C. supervised A.T. for cellular studies using DNA fiber assay. P.C. con-
969 ceived, supervised and wrote the manuscript with input from S.H.

970

971 FIGURE LEGENDS

972 **Figure 1. SMARCAL1, ZRANB3 and HLTF possess distinct biochemical activities**

973 (a) Recombinant SMARCAL1, ZRANB3, and HLTF were analyzed by polyacrylamide gel electropho-
974 resis and stained with Coomassie Brilliant Blue.

975 (b) A schematic of replication fork reversal assay (leading and lagging strand gap structure is shown).

976 (c) Fork reversal assays with SMARCAL1, ZRANB3 and HLTF with RPA (3 nM). Top, quantifications
977 (error bars show SEM of three replicates); bottom, representative experiments.

978 (d) Fork reversal assays with HLTF without or with RPA (3 nM). Top, quantifications (error bars indi-
979 cate SEM of three replicates); bottom, representative experiments.

980 (e) A schematic of Holliday junction branch migration assay.

981 (f) Holliday junction branch migrations assay with SMARCAL1, ZRANB3 and HLTF. Top, quantifi-
982 cations (error bars indicate SEM of three replicates); bottom, representative experiments.

983 (g) A schematic of topoisomerase-coupled annealing assay.

984 (h) Comparison of SMARCAL1, ZRANB3 and HLTF in topoisomerase-coupled annealing assays.
985 ATP hydrolysis by HLTF is required, as no detectable annealing was observed without ATP.

986

987

988 **Figure 2. SMARCAL1 anneals RPA-coated ssDNA**

989 (a) A schematic of ssDNA annealing assays.

990 (b) Annealing of ssDNA by SMARCAL1, ZRANB3 and HLTf without or with RPA (4 nM). Repre-
991 sentative experiments are shown.

992 (c) Quantification of experiment as in (b) at 30 minutes (error bars indicate SEM of three replicates).

993 (d) Annealing of ssDNA by SMARCAL1 without or with human mitochondrial SSB (4 nM). Top,
994 quantifications (error bars indicate SEM of three replicates); bottom, representative experiments.

995 (e) Top, a schematic showing domain organization of SMARCAL1. RPA binding domain is located in
996 the N-terminal part of SMARCAL1 (indicated in dark blue). SMARCAL1 Δ N lacking RPA binding
997 domain is shown below.

998 (f) Recombinant SMARCAL1-WT and SMARCAL1 Δ N were analyzed by polyacrylamide gel electro-
999 phoresis and stained with Coomassie Brilliant Blue.

1000 (g) A comparison of SMARCAL1-WT and SMARCAL1 Δ N in ssDNA annealing without or with RPA
1001 (4 nM). Top, quantifications (error bars indicate SEM of three replicates); bottom, representative ex-
1002 periments.

1003

1004

1005 **Figure 3. RAD51 and BCDX2 promote SMARCAL1 and ZRANB3 mediated branch migration**
1006 **and DNA annealing**

1007 (a) Recombinant RAD51 and BCDX2 were analyzed by polyacrylamide gel electrophoresis and stained
1008 with Coomassie Brilliant Blue.

1009 (b) Annealing helicase assay. RAD51 and BCDX2 separately stimulate SMARCAL1-mediated anneal-
1010 ing of RPA-coated ssDNA. Top, quantifications (error bars indicate SEM of four replicates); bottom,
1011 representative experiment. Statistical significance; *($P < 0.05$), ***($P < 0.001$), two-tailed t-test.

1012 (c) RAD51 and BCDX2 separately promote ZRANB3 mediated strand annealing. Top, quantifica-
1013 tions (error bars indicate SEM of four replicates); bottom, representative experiment. Statistical sig-
1014 nificance bars; ns ($P > 0.05$, not significant); **($P < 0.01$); two-tailed t-test.

1015 (d) RAD51 and BCDX2 do not promote HLTf-mediated DNA annealing. Shown is a representative
1016 experiment.

1017

1018 **Figure 4. SMARCAL1 and ZRANB3 physically interact with RAD51 and BCDX2**

1019 (a) Soluble extract from *E. coli* containing MBP-RAD51 (bait) was immobilized on amylose resin and
1020 incubated with purified recombinant proteins (RAD51 paralogs, ZRANB3, SMARCAL1, [prey]) as
1021 indicated. Western blot analyses were performed with anti-MBP and anti-FLAG antibodies.

1022 (b) and (c) Anti-His antibody was coupled to Protein G agarose, bound to the BCDX2 complex (bait)
1023 and tested for interaction with ZRANB3 (prey) or SMARCAL1 (prey), respectively. Samples were
1024 subjected to either silver staining or Western blot analysis by anti-FLAG and anti-His antibodies.
1025 (d) Multiple sequence alignment showing the presence of a consensus FxxA motif in SMARCAL1
1026 along with previously characterized RAD51 interacting proteins or BRCA2 domains (highlighted in
1027 grey with bold red letters).
1028 (e) Recombinant SMARCAL1-WT and SMARCAL1-F446A were analyzed by polyacrylamide gel
1029 electrophoresis and stained with Coomassie Brilliant Blue.
1030 (f) SMARCAL1-F446A fails to interact with RAD51. Soluble extract from *E. coli* containing MBP-
1031 RAD51 (bait) was immobilized on amylose resin and incubated with purified recombinant
1032 SMARCAL1 variants (prey). Ponceau staining shows RAD51. Western blot analysis was performed
1033 with anti-FLAG antibody to detect SMARCAL1.
1034 (g) SMARCAL1-F446A, as SMARCAL1-WT, interacts with the BCDX2 complex. Anti-His antibody
1035 was immobilized on protein G agarose, bound to BCDX2 complex (bait) and tested for interaction with
1036 SMARCAL1 variants (prey). Samples were subjected to silver staining.
1037 (h) DNA fiber assay to monitor SMARCAL1-mediated nascent DNA degradation in BRCA1-deficient
1038 cells. Wild type or SMARCAL1-F446A proteins were expressed in SMARCAL1 KO MCF10A cells
1039 upon BRCA1 depletion, as indicated. SMARCAL1-deficiency renders BRCA1-depleted cells resistant
1040 to replication fork degradation upon hydroxyurea (HU) treatment, as a result of impaired fork reversal.
1041 Top: a schematic of the assay: CldU (25 minutes), IdU (35 minutes) pulse-labeling protocol to evaluate
1042 fork degradation upon HU treatment. Under wild type condition the ratio of IdU/CldU tract length will
1043 remain ~ 1 , however if there is fork degradation this ratio will be < 1 . Bottom: graphical representation
1044 of IdU/CldU tract length ratio. The median value of 100 or more IdU and CldU tracts per experimental
1045 condition is indicated. Statistical analysis was conducted using Mann-Whitney test (**** $p < 0.0001$).
1046 Data are representative of two independent experiments.

1047
1048

1049 **Figure 5. RAD51 protects DNA from degradation by MRE11, EXO1 and DNA2 nucleases**

1050 (a) Top, a schematic of the assay. Bottom, endonuclease activity of MRN-pCtIP on quadruple blocked
1051 5'-end-labeled 70 bp-long dsDNA is efficiently inhibited by RAD51-WT and RAD51-K133R but not
1052 by RAD51-K133A, RAD51-Y232A or RAD51-T131P mutants. Reaction products were separated by
1053 15% denaturing polyacrylamide gel electrophoresis. In the schematic at the top, asterisk indicates the
1054 position of the radioactive label.
1055 (b) Quantification of experiments such as in panel (a) (error bars indicate SEM of three replicates).
1056 The level of DNA protection by RAD51 is presented as a relative value with respect to DNA degrada-
1057 tion without RAD51 (lane 2 in panel a).

1058 (c) Top, a schematic of the assay. Bottom, RAD51-WT and ATP-hydrolysis deficient K133R mutant
1059 efficiently protect DNA against the exonuclease activity of MR (MRE11-RAD50). RAD51 variants
1060 (RAD51-K133A, RAD51-Y232A or RAD51-T131P) with decreased DNA binding capacity failed to
1061 inhibit MR. 5'-end-labeled 50 bp-long dsDNA was used as a substrate. Asterisk indicates the position
1062 of the ³²P label. Reaction products were separated by 15% denaturing polyacrylamide gel electropho-
1063 resis.

1064 (d) Quantification of experiments such as shown in panel (c), error bars indicate SEM of three repli-
1065 cates. The level of DNA protection by RAD51 is presented as a relative value with respect to DNA
1066 degradation without RAD51 (lane 2 in panel c).

1067 (e) RAD51 efficiently protects against the exonuclease activity of MR on a 5'-end-labeled 50 bp-long
1068 dsDNA in presence of ATP. Reaction products were separated by 15% denaturing polyacrylamide gel
1069 electrophoresis. Top, quantifications (error bars indicate SEM of three replicates); bottom, a representa-
1070 tive experiment.

1071 (f) ATP-bound RAD51 efficiently protects against EXO1 on a 3'-end-labeled 50 bp-long dsDNA. Cal-
1072 cium (1 mM) traps ATP-bound RAD51 on DNA, which greatly enhances RAD51-mediated protection.
1073 Reaction products were separated by 15% denaturing polyacrylamide gel electrophoresis.

1074 (g) Quantifications of experiments such as in panel (f), error bars indicate SEM of at least three repli-
1075 cates.

1076 (h) Top, a schematic of the assay. Bottom, RAD51-WT and RAD51-K133R, but not RAD51-K133A
1077 variant efficiently protect against EXO1 degradation, using a 5'-end-labeled 50 bp-long dsDNA as a
1078 substrate. Asterisk indicates the position of the ³²P label. Reaction products were separated by 15%
1079 denaturing polyacrylamide gel electrophoresis.

1080 (i) Quantification of experiments such as shown in panel (h); error bars indicate SEM of three replicates.
1081 The level of DNA protection by RAD51 is presented as a relative value with respect to DNA degrada-
1082 tion without RAD51 (lane 2 in panel h).

1083 (j) Top, a schematic of the assay. Bottom, DNA degradation by WRN, DNA2 and RPA is inhibited by
1084 RAD51. 2.2-kilobase pair (kbp)-long randomly labeled dsDNA was used as the substrate. Reaction
1085 products were separated by 1% agarose gel electrophoresis. Red asterisks indicate random DNA label-
1086 ing.

1087 (k) Quantification of experiments such as shown in panel (j); error bars indicate SEM of three replicates.
1088 The level of DNA protection by RAD51 is presented as a relative value with respect to DNA degrada-
1089 tion without RAD51 (lane 4 in panel j).

1090

1091

1092 **Figure 6. Nucleolytic degradation is prevented by RAD51 upon binding to dsDNA**

1093 (a) Nuclease assays with MRE11-RAD50 (MR) and their inhibition by RAD51. The experiments were
1094 carried out with blunt-ended, 5'-overhanged or 3'-overhanged DNA. Asterisk indicates the position of

1095 the labelling. Reaction products were separated by 15% denaturing polyacrylamide gel electrophoresis.
1096 A representative experiment is shown.

1097 (b) Quantifications of experiments such as shown in panel (a), error bars indicate SEM of three repli-
1098 cates. The level of DNA protection by RAD51 is presented as a relative value with respect to DNA
1099 degradation for each substrate without RAD51 (lanes 3, 7 and 11 in panel a).

1100 (c) Nuclease assays with EXO1 and its inhibition by RAD51. Experiments were carried out with blunt-
1101 ended, 5'-overhanged or 3'-overhanged DNA. Asterisk indicates the position of the ³²P label. Reaction
1102 products were separated by 15% denaturing polyacrylamide gel electrophoresis. Shown is a representa-
1103 tive experiment.

1104 (d) Quantifications of experiments such as shown in panel (c), error bars indicate SEM of three repli-
1105 cates. The level of DNA protection by RAD51 is presented as a relative value with respect to DNA
1106 degradation for each substrate without RAD51 (lanes 2, 7 and 12 in panel c).

1107

1108 **Figure 7. Model for replication fork reversal and protection.**

1109 Fork remodelers have unequal biochemical functions. SMARCAL1 anneals RPA-coated ssDNA and
1110 may promote initial steps in fork reversal. ZRANB3 and HLTF are more proficient in branch migration.
1111 RAD51 and BCDX2 interact with SMARCAL1 and ZRANB3 and stimulate their activities. Reversed
1112 replication forks are prone to pathological degradation, in certain genetic backgrounds, unless protected
1113 by RAD51. We show that unexpectedly the dsDNA-binding capacity of RAD51 promotes DNA pro-
1114 tection against nucleases.

1115

1116

1117

1118

1119

1120

1121 **REFERENCES**

1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169

1. Ranjha L, Howard SM, Cejka P. Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes. *Chromosoma* **127**, 187-214 (2018).
2. Kawale AS, Sung P. Mechanism and significance of chromosome damage repair by homologous recombination. *Essays Biochem*, (2020).
3. Anand R, Ranjha L, Cannavo E, Cejka P. Phosphorylated CtIP Functions as a Co-factor of the MRE11-RAD50-NBS1 Endonuclease in DNA End Resection. *Mol Cell* **64**, 940-950 (2016).
4. Reginato G, Cejka P. The MRE11 complex: A versatile toolkit for the repair of broken DNA. *DNA Repair (Amst)* **91-92**, 102869 (2020).
5. Bonetti D, Colombo CV, Clerici M, Longhese MP. Processing of DNA Ends in the Maintenance of Genome Stability. *Front Genet* **9**, 390 (2018).
6. Sigurdsson S, Van Komen S, Bussen W, Schild D, Albala JS, Sung P. Mediator function of the human Rad51B-Rad51C complex in Rad51/RPA-catalyzed DNA strand exchange. *Genes Dev* **15**, 3308-3318 (2001).
7. Roy U, *et al.* The Rad51 paralog complex Rad55-Rad57 acts as a molecular chaperone during homologous recombination. *Mol Cell*, (2021).
8. Belan O, *et al.* Single-molecule analysis reveals cooperative stimulation of Rad51 filament nucleation and growth by mediator proteins. *Mol Cell*, (2021).
9. Schlacher K, Christ N, Siaud N, Egashira A, Wu H, Jasin M. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. *Cell* **145**, 529-542 (2011).
10. Hashimoto Y, Ray Chaudhuri A, Lopes M, Costanzo V. Rad51 protects nascent DNA from Mre11-dependent degradation and promotes continuous DNA synthesis. *Nat Struct Mol Biol* **17**, 1305-1311 (2010).
11. Zeman MK, Cimprich KA. Causes and consequences of replication stress. *Nat Cell Biol* **16**, 2-9 (2014).
12. Tirman S, *et al.* Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells. *Mol Cell* **81**, 4026-4040 e4028 (2021).
13. Tagliatalata A, *et al.* REV1-Polzeta maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps. *Mol Cell* **81**, 4008-4025 e4007 (2021).
14. Cortez D. Replication-Coupled DNA Repair. *Mol Cell* **74**, 866-876 (2019).

- 1170 15. Ray Chaudhuri A, *et al.* Topoisomerase I poisoning results in PARP-mediated
1171 replication fork reversal. *Nat Struct Mol Biol* **19**, 417-423 (2012).
1172
- 1173 16. Berti M, Cortez D, Lopes M. The plasticity of DNA replication forks in response to
1174 clinically relevant genotoxic stress. *Nat Rev Mol Cell Biol* **21**, 633-651 (2020).
1175
- 1176 17. Zellweger R, *et al.* Rad51-mediated replication fork reversal is a global response to
1177 genotoxic treatments in human cells. *J Cell Biol* **208**, 563-579 (2015).
1178
- 1179 18. Sogo JM, Lopes M, Foiani M. Fork reversal and ssDNA accumulation at stalled
1180 replication forks owing to checkpoint defects. *Science* **297**, 599-602 (2002).
1181
- 1182 19. Joseph SA, Taglialatela A, Leuzzi G, Huang JW, Cuella-Martin R, Ciccio A. Time for
1183 remodeling: SNF2-family DNA translocases in replication fork metabolism and human
1184 disease. *DNA Repair (Amst)* **95**, 102943 (2020).
1185
- 1186 20. Neelsen KJ, Lopes M. Replication fork reversal in eukaryotes: from dead end to
1187 dynamic response. *Nat Rev Mol Cell Biol* **16**, 207-220 (2015).
1188
- 1189 21. Ciccio A, *et al.* The SIOD disorder protein SMARCAL1 is an RPA-interacting protein
1190 involved in replication fork restart. *Genes Dev* **23**, 2415-2425 (2009).
1191
- 1192 22. Ciccio A, *et al.* Polyubiquitinated PCNA recruits the ZRANB3 translocase to maintain
1193 genomic integrity after replication stress. *Molecular cell* **47**, 396-409 (2012).
1194
- 1195 23. Yuan J, Ghosal G, Chen J. The annealing helicase HARP protects stalled replication
1196 forks. *Genes Dev* **23**, 2394-2399 (2009).
1197
- 1198 24. Yuan J, Ghosal G, Chen J. The HARP-like domain-containing protein AH2/ZRANB3
1199 binds to PCNA and participates in cellular response to replication stress. *Mol Cell* **47**,
1200 410-421 (2012).
1201
- 1202 25. Bansbach CE, Betous R, Lovejoy CA, Glick GG, Cortez D. The annealing helicase
1203 SMARCAL1 maintains genome integrity at stalled replication forks. *Genes Dev* **23**,
1204 2405-2414 (2009).
1205
- 1206 26. Weston R, Peeters H, Ahel D. ZRANB3 is a structure-specific ATP-dependent
1207 endonuclease involved in replication stress response. *Genes Dev* **26**, 1558-1572 (2012).
1208
- 1209 27. Kolinjivadi AM, *et al.* Smarcal1-Mediated Fork Reversal Triggers Mre11-Dependent
1210 Degradation of Nascent DNA in the Absence of Brca2 and Stable Rad51
1211 Nucleofilaments. *Mol Cell* **67**, 867-881 e867 (2017).
1212
- 1213 28. Schlacher K, Wu H, Jasin M. A distinct replication fork protection pathway connects
1214 Fanconi anemia tumor suppressors to RAD51-BRCA1/2. *Cancer Cell* **22**, 106-116
1215 (2012).
1216
- 1217 29. Zadorozhny K, *et al.* Fanconi-Anemia-Associated Mutations Destabilize RAD51
1218 Filaments and Impair Replication Fork Protection. *Cell Rep* **21**, 333-340 (2017).
1219

- 1220 30. Lemacon D, *et al.* MRE11 and EXO1 nucleases degrade reversed forks and elicit
1221 MUS81-dependent fork rescue in BRCA2-deficient cells. *Nat Commun* **8**, 860 (2017).
1222
- 1223 31. Mijic S, *et al.* Replication fork reversal triggers fork degradation in BRCA2-defective
1224 cells. *Nat Commun* **8**, 859 (2017).
1225
- 1226 32. Higgs MR, *et al.* BOD1L Is Required to Suppress Deleterious Resection of Stressed
1227 Replication Forks. *Mol Cell* **59**, 462-477 (2015).
1228
- 1229 33. Xu S, *et al.* Abro1 maintains genome stability and limits replication stress by protecting
1230 replication fork stability. *Genes Dev* **31**, 1469-1482 (2017).
1231
- 1232 34. Higgs MR, *et al.* Histone Methylation by SETD1A Protects Nascent DNA through the
1233 Nucleosome Chaperone Activity of FANCD2. *Mol Cell* **71**, 25-41 e26 (2018).
1234
- 1235 35. Thangavel S, *et al.* DNA2 drives processing and restart of reversed replication forks in
1236 human cells. *J Cell Biol* **208**, 545-562 (2015).
1237
- 1238 36. Tagliatalata A, *et al.* Restoration of Replication Fork Stability in BRCA1- and BRCA2-
1239 Deficient Cells by Inactivation of SNF2-Family Fork Remodelers. *Mol Cell* **68**, 414-
1240 430 e418 (2017).
1241
- 1242 37. Bhat KP, Cortez D. RPA and RAD51: fork reversal, fork protection, and genome
1243 stability. *Nat Struct Mol Biol* **25**, 446-453 (2018).
1244
- 1245 38. Mason JM, Chan YL, Weichselbaum RW, Bishop DK. Non-enzymatic roles of human
1246 RAD51 at stalled replication forks. *Nat Commun* **10**, 4410 (2019).
1247
- 1248 39. Berti M, *et al.* Sequential role of RAD51 paralog complexes in replication fork
1249 remodeling and restart. *Nat Commun* **11**, 3531 (2020).
1250
- 1251 40. Vujanovic M, *et al.* Replication Fork Slowing and Reversal upon DNA Damage
1252 Require PCNA Polyubiquitination and ZRANB3 DNA Translocase Activity. *Mol Cell*
1253 **67**, 882-890 e885 (2017).
1254
- 1255 41. Betous R, *et al.* SMARCAL1 catalyzes fork regression and Holliday junction migration
1256 to maintain genome stability during DNA replication. *Genes Dev* **26**, 151-162 (2012).
1257
- 1258 42. Betous R, Couch FB, Mason AC, Eichman BF, Manosas M, Cortez D. Substrate-
1259 selective repair and restart of replication forks by DNA translocases. *Cell Rep* **3**, 1958-
1260 1969 (2013).
1261
- 1262 43. Yusufzai T, Kadonaga JT. HARP is an ATP-driven annealing helicase. *Science* **322**,
1263 748-750 (2008).
1264
- 1265 44. Yusufzai T, Kadonaga JT. Annealing helicase 2 (AH2), a DNA-rewinding motor with
1266 an HNH motif. *Proc Natl Acad Sci U S A* **107**, 20970-20973 (2010).
1267

- 1268 45. Khadka P, Croteau DL, Bohr VA. RECQL5 has unique strand annealing properties
1269 relative to the other human RecQ helicase proteins. *DNA Repair (Amst)* **37**, 53-66
1270 (2016).
1271
- 1272 46. Garcia PL, Liu Y, Jiricny J, West SC, Janscak P. Human RECQ5beta, a protein with
1273 DNA helicase and strand-annealing activities in a single polypeptide. *EMBO J* **23**,
1274 2882-2891 (2004).
1275
- 1276 47. Mortensen UH, Bendixen C, Sunjevaric I, Rothstein R. DNA strand annealing is
1277 promoted by the yeast Rad52 protein. *Proc Natl Acad Sci U S A* **93**, 10729-10734
1278 (1996).
1279
- 1280 48. Sugiyama T, New JH, Kowalczykowski SC. DNA annealing by RAD52 protein is
1281 stimulated by specific interaction with the complex of replication protein A and single-
1282 stranded DNA. *Proc Natl Acad Sci U S A* **95**, 6049-6054 (1998).
1283
- 1284 49. Berti M, *et al.* Human RECQ1 promotes restart of replication forks reversed by DNA
1285 topoisomerase I inhibition. *Nat Struct Mol Biol* **20**, 347-354 (2013).
1286
- 1287 50. Masson JY, *et al.* Identification and purification of two distinct complexes containing
1288 the five RAD51 paralogs. *Genes Dev* **15**, 3296-3307 (2001).
1289
- 1290 51. Somyajit K, Saxena S, Babu S, Mishra A, Nagaraju G. Mammalian RAD51 paralogs
1291 protect nascent DNA at stalled forks and mediate replication restart. *Nucleic Acids Res*
1292 **43**, 9835-9855 (2015).
1293
- 1294 52. Rodrigue A, *et al.* Interplay between human DNA repair proteins at a unique double-
1295 strand break in vivo. *EMBO J* **25**, 222-231 (2006).
1296
- 1297 53. Scott DE, Marsh M, Blundell TL, Abell C, Hyvonen M. Structure-activity relationship
1298 of the peptide binding-motif mediating the BRCA2:RAD51 protein-protein interaction.
1299 *FEBS Lett* **590**, 1094-1102 (2016).
1300
- 1301 54. Schwendener S, *et al.* Physical interaction of RECQ5 helicase with RAD51 facilitates
1302 its anti-recombinase activity. *J Biol Chem* **285**, 15739-15745 (2010).
1303
- 1304 55. Matsuzaki K, Kondo S, Ishikawa T, Shinohara A. Human RAD51 paralogue SWSAP1
1305 fosters RAD51 filament by regulating the anti-recombinase FIGNL1 AAA+ ATPase.
1306 *Nat Commun* **10**, 1407 (2019).
1307
- 1308 56. Yuan J, Chen J. FIGNL1-containing protein complex is required for efficient
1309 homologous recombination repair. *Proc Natl Acad Sci U S A* **110**, 10640-10645 (2013).
1310
- 1311 57. Piwko W, *et al.* The MMS22L-TONSL heterodimer directly promotes RAD51-
1312 dependent recombination upon replication stress. *EMBO J* **35**, 2584-2601 (2016).
1313
- 1314 58. Pellegrini L, *et al.* Insights into DNA recombination from the structure of a RAD51-
1315 BRCA2 complex. *Nature* **420**, 287-293 (2002).
1316

- 1317 59. Badu-Nkansah A, Mason AC, Eichman BF, Cortez D. Identification of a Substrate
1318 Recognition Domain in the Replication Stress Response Protein Zinc Finger Ran-
1319 binding Domain-containing Protein 3 (ZRANB3). *J Biol Chem* **291**, 8251-8257 (2016).
1320
- 1321 60. Symington LS. Mechanism and regulation of DNA end resection in eukaryotes. *Critical*
1322 *reviews in biochemistry and molecular biology*, 1-18 (2016).
1323
- 1324 61. Chi P, Van Komen S, Sehorn MG, Sigurdsson S, Sung P. Roles of ATP binding and
1325 ATP hydrolysis in human Rad51 recombinase function. *DNA Repair (Amst)* **5**, 381-391
1326 (2006).
1327
- 1328 62. Wang AT, *et al.* A Dominant Mutation in Human RAD51 Reveals Its Function in DNA
1329 Interstrand Crosslink Repair Independent of Homologous Recombination. *Mol Cell* **59**,
1330 478-490 (2015).
1331
- 1332 63. Matsuo Y, Sakane I, Takizawa Y, Takahashi M, Kurumizaka H. Roles of the human
1333 Rad51 L1 and L2 loops in DNA binding. *FEBS J* **273**, 3148-3159 (2006).
1334
- 1335 64. Jensen RB, Carreira A, Kowalczykowski SC. Purified human BRCA2 stimulates
1336 RAD51-mediated recombination. *Nature* **467**, 678-683 (2010).
1337
- 1338 65. Carreira A, *et al.* The BRC repeats of BRCA2 modulate the DNA-binding selectivity
1339 of RAD51. *Cell* **136**, 1032-1043 (2009).
1340
- 1341 66. Esashi F, Galkin VE, Yu X, Egelman EH, West SC. Stabilization of RAD51
1342 nucleoprotein filaments by the C-terminal region of BRCA2. *Nat Struct Mol Biol* **14**,
1343 468-474 (2007).
1344
- 1345 67. Cannavo E, Cejka P, Kowalczykowski SC. Relationship of DNA degradation by
1346 *Saccharomyces cerevisiae* exonuclease 1 and its stimulation by RPA and Mre11-
1347 Rad50-Xrs2 to DNA end resection. *Proc Natl Acad Sci US A* **110**, E1661-1668 (2013).
1348
- 1349 68. Bai G, *et al.* HLTF Promotes Fork Reversal, Limiting Replication Stress Resistance
1350 and Preventing Multiple Mechanisms of Unrestrained DNA Synthesis. *Mol Cell* **78**,
1351 1237-1251 e1237 (2020).
1352
- 1353 69. Tian T, *et al.* The ZATT-TOP2A-PICH Axis Drives Extensive Replication Fork
1354 Reversal to Promote Genome Stability. *Mol Cell* **81**, 198-211 e196 (2021).
1355
- 1356 70. Poole LA, Cortez D. Functions of SMARCAL1, ZRANB3, and HLTF in maintaining
1357 genome stability. *Crit Rev Biochem Mol Biol* **52**, 696-714 (2017).
1358
- 1359 71. Taylor MR, *et al.* Rad51 Paralogs Remodel Pre-synaptic Rad51 Filaments to Stimulate
1360 Homologous Recombination. *Cell* **162**, 271-286 (2015).
1361
- 1362 72. Liu J, Renault L, Veaute X, Fabre F, Stahlberg H, Heyer WD. Rad51 paralogues Rad55-
1363 Rad57 balance the antirecombinase Srs2 in Rad51 filament formation. *Nature* **479**, 245-
1364 248 (2011).
1365

- 1366 73. Serra H, Da Ines O, Degroote F, Gallego ME, White CI. Roles of XRCC2, RAD51B
1367 and RAD51D in RAD51-independent SSA recombination. *PLoS Genet* **9**, e1003971
1368 (2013).
1369
- 1370 74. Takata K, Reh S, Tomida J, Person MD, Wood RD. Human DNA helicase HELQ
1371 participates in DNA interstrand crosslink tolerance with ATR and RAD51 paralogs.
1372 *Nat Commun* **4**, 2338 (2013).
1373
- 1374 75. Bhat KP, Krishnamoorthy A, Dungrawala H, Garcin EB, Modesti M, Cortez D. RADX
1375 Modulates RAD51 Activity to Control Replication Fork Protection. *Cell Rep* **24**, 538-
1376 545 (2018).
1377
- 1378 76. Benson FE, Stasiak A, West SC. Purification and characterization of the human Rad51
1379 protein, an analogue of E. coli RecA. *EMBO J* **13**, 5764-5771 (1994).
1380
- 1381 77. Sung P, Robberson DL. DNA strand exchange mediated by a RAD51-ssDNA
1382 nucleoprotein filament with polarity opposite to that of RecA. *Cell* **82**, 453-461 (1995).
1383
- 1384 78. Kowalczykowski SC. An Overview of the Molecular Mechanisms of Recombinational
1385 DNA Repair. *Cold Spring Harbor perspectives in biology* **7**, (2015).
1386
- 1387 79. Reginato G, Cannavo E, Cejka P. Physiological protein blocks direct the Mre11-Rad50-
1388 Xrs2 and Sae2 nuclease complex to initiate DNA end resection. *Genes Dev* **31**, 2325-
1389 2330 (2017).
1390
- 1391 80. Daza-Martin M, *et al.* Isomerization of BRCA1-BARD1 promotes replication fork
1392 protection. *Nature* **571**, 521-527 (2019).
1393
- 1394 81. Howard SM, Ceppi I, Anand R, Geiger R, Cejka P. The internal region of CtIP
1395 negatively regulates DNA end resection. *Nucleic Acids Res* **48**, 5485-5498 (2020).
1396
- 1397 82. Fyodorov DV, Kadonaga JT. Chromatin assembly in vitro with purified recombinant
1398 ACF and NAP-1. *Methods Enzymol* **371**, 499-515 (2003).
1399
- 1400 83. Anand R, Pinto C, Cejka P. Methods to Study DNA End Resection I: Recombinant
1401 Protein Purification. *Methods Enzymol* **600**, 25-66 (2018).
1402
- 1403 84. Pinto C, Kasaciunaite K, Seidel R, Cejka P. Human DNA2 possesses a cryptic DNA
1404 unwinding activity that functionally integrates with BLM or WRN helicases. *Elife* **5**,
1405 (2016).
1406
- 1407 85. Anand R, *et al.* NBS1 promotes the endonuclease activity of the MRE11-RAD50
1408 complex by sensing CtIP phosphorylation. *EMBO J* **38**, (2019).
1409
- 1410 86. Ceppi I, *et al.* CtIP promotes the motor activity of DNA2 to accelerate long-range DNA
1411 end resection. *Proc Natl Acad Sci U S A* **117**, 8859-8869 (2020).
1412
- 1413 87. Cannavo E, Reginato G, Cejka P. Stepwise 5' DNA end-specific resection of DNA
1414 breaks by the Mre11-Rad50-Xrs2 and Sae2 nuclease ensemble. *Proc Natl Acad Sci U*
1415 *S A* **116**, 5505-5513 (2019).

- 1416
1417 88. Cannavo E, *et al.* Regulatory control of DNA end resection by Sae2 phosphorylation.
1418 *Nat Commun* **9**, 4016 (2018).
1419
- 1420 89. Cannavo E, Cejka P. Sae2 promotes dsDNA endonuclease activity within Mre11-
1421 Rad50-Xrs2 to resect DNA breaks. *Nature* **514**, 122-125 (2014).
1422
- 1423 90. Pinto C, Anand R, Cejka P. Methods to Study DNA End Resection II: Biochemical
1424 Reconstitution Assays. *Methods Enzymol* **600**, 67-106 (2018).
1425
- 1426 91. Gari K, Decaillet C, Stasiak AZ, Stasiak A, Constantinou A. The Fanconi anemia
1427 protein FANCM can promote branch migration of Holliday junctions and replication
1428 forks. *Mol Cell* **29**, 141-148 (2008).
1429
- 1430 92. Cejka P, Kowalczykowski SC. The full-length *Saccharomyces cerevisiae* Sgs1 protein
1431 is a vigorous DNA helicase that preferentially unwinds holliday junctions. *J Biol Chem*
1432 **285**, 8290-8301 (2010).
1433
- 1434 93. Guarani V, Paulo J, Zhai B, Huttlin EL, Gygi SP, Harper JW. TIMMDC1/C3orf1
1435 functions as a membrane-embedded mitochondrial complex I assembly factor through
1436 association with the MCIA complex. *Mol Cell Biol* **34**, 847-861 (2014).
1437
1438




Figure 2. SMARCAL1 anneals RPA-coated ssDNA

(a) A schematic of ssDNA annealing assays.

(b) Annealing of ssDNA by SMARCAL1, ZRANB3 and HLTF without or with RPA. Representative experiments are shown.

(c) Quantification of (b) at 30 minutes (error bars indicate SEM of three replicates).

(d) Annealing of ssDNA by SMARCAL1 without or with human mitochondrial SSB. Top, quantifications (error bars indicate SEM of three replicates); bottom, representative experiments.

(e) Top, a schematic showing domain organization of SMARCAL1. RPA binding domain is located in the N-terminal part of SMARCAL1 (indicated in dark blue). SMARCAL1ΔN lacking RPA binding domain is shown below.

(f) Recombinant SMARCAL1-WT and SMARCAL1ΔN were analyzed by polyacrylamide gel electrophoresis and stained with Coomassie Brilliant Blue.

(g) A comparison of SMARCAL1-WT and SMARCAL1ΔN in ssDNA annealing without or with RPA. Top, quantifications (error bars indicate SEM of three replicates); bottom, representative experiments.

- (c) Top, a schematic of the assay. Bottom, RAD51-WT and ATP-hydrolysis deficient K133R mutant efficiently protect DNA against the exonuclease activity of MR (MRE11-RAD50). RAD51 variants (RAD51-K133A, RAD51-Y232A or RAD51-T131P) with decreased DNA binding capacity failed to inhibit MR. 5'-end-labeled 50 bp-long dsDNA was used as a substrate. Asterisk indicates the position of the ³²P label. Reaction products were separated by 15% denaturing polyacrylamide gel electrophoresis.
- (d) Quantification of experiments such as shown in panel (c), error bars indicate SEM of three replicates. The level of DNA protection by RAD51 is presented as a relative value with respect to DNA degradation without RAD51 (lane 2 in panel c).
- (e) RAD51 efficiently protects against the exonuclease activity of MR on a 5'-end-labeled 50 bp-long dsDNA in presence of ATP. Top, quantifications (error bars indicate SEM of three replicates); bottom, a representative experiment.
- (f) ATP-bound RAD51 efficiently protects against EXO1 on a 5'-end-labeled 50 bp-long dsDNA. Calcium (1 mM) traps ATP-bound RAD51 on DNA, which greatly enhances RAD51-mediated protection.
- (g) Quantifications of experiments such as in panel (f), error bars indicate SEM of at least three replicates.
- (h) Top, a schematic of the assay. Bottom, RAD51-WT and RAD51-K133R, but not RAD51-K133A variants efficiently protect against EXO1 degradation, using a 5'-end-labeled 50 bp-long dsDNA as a substrate. Asterisk indicates the position of the ³²P label. Reaction products were separated by 15% denaturing polyacrylamide gel electrophoresis.
- (i) Quantification of experiments such as shown in panel (h); error bars indicate SEM of three replicates. The level of DNA protection by RAD51 is presented as a relative value with respect to DNA degradation without RAD51 (lane 2 in panel h).
- (j) Top, a schematic of the assay. Bottom, DNA degradation by WRN, DNA2 and RPA is inhibited by RAD51. 2.2-kilobase pair (kbp)-long randomly labeled dsDNA was used as the substrate. Reaction products were separated by 1% agarose gel electrophoresis. Red asterisks indicate random DNA labeling.
- (k) Quantification of experiments such as shown in panel (j); error bars indicate SEM of three replicates. The level of DNA protection by RAD51 is presented as a relative value with respect to DNA degradation without RAD51 (lane 4 in panel j).




Figure 6. Nucleolytic degradation is prevented by RAD51 upon binding to dsDNA

(a) Nuclease assays with MRE11-RAD50 (MR) and their inhibition by RAD51. The experiments were carried out with blunt-ended, 5'-overhanged or 3'-overhanged DNA. Asterisk indicates the position of the labelling. Reaction products were separated by 15% denaturing polyacrylamide gel electrophoresis. A representative experiment is shown.

(b) Quantifications of experiments such as shown in panel (a), error bars indicate SEM of three replicates. The level of DNA protection by RAD51 is presented as a relative value with respect to DNA degradation for each substrate without RAD51 (lanes 3, 7 and 11 in panel a).

(c) Nuclease assays with EXO1 and its inhibition by RAD51. Experiments were carried out with blunt-ended, 5'-overhanged or 3'-overhanged DNA. Asterisk indicates the position of the ^{32}P label. Reaction products were separated by 15% denaturing polyacrylamide gel electrophoresis. Shown is a representative experiment.

(d) Quantifications of experiments such as shown in panel (c), error bars indicate SEM of three replicates. The level of DNA protection by RAD51 is presented as a relative value with respect to DNA degradation for each substrate without RAD51 (lanes 2, 7 and 12 in panel c).




Figure 7. Model for replication fork reversal and protection.

Fork remodelers have unequal biochemical functions. SMARCAL1 anneals RPA-coated ssDNA and may promote initial steps in fork reversal. ZRANB3 and HLF are more proficient in branch migration. RAD51 and BCDX2 interact with SMARCAL1 and ZRANB3 and promote their activities. Reversed replication forks are prone to pathological degradation, in certain genetic backgrounds, unless protected by RAD51. We show that unexpectedly the dsDNA-binding capacity of RAD51 promotes DNA protection against nucleases.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [HalderSupplementaryInformation.pdf](#)
- [Halderreportingsummaryflatten.pdf](#)